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Résumé 
 
Dans beaucoup de pays d’Afrique, d’Asie, du Moyen et du Proche Orient, les 
petits ruminants payent un lourd tribut à deux maladies hautement contagieuses, la peste 
des petits ruminants et la variole des petits ruminants. La Peste des petits ruminants 
(PPR) connue aussi dans le passé sous le nom de peste caprine est une maladie virale 
hautement contagieuse affectant les petits ruminants domestiques et sauvages. Elle est 
due à un virus de la famille des Paramyxoviridae appartenant au genre Morbillivirus: le 
virus de la Peste des Petits Ruminants (PPRV). C’est une affection des chèvres et des 
moutons semblable à la peste bovine. Elle est caractérisée par une stomatite nécrosante, 
une entérite et une pneumonie grave aboutissant très souvent à la mort. Elle constitue la 
maladie la plus importante des petits ruminants dans les endroits où elle est endémique,  
les pays d’Afrique situés entre le Sahara et l’Equateur, le Moyen et Proche Orient et le 
Sud-Ouest Asiatique. Dans ces mêmes régions, sévit une autre maladie contagieuse 
virale, la variole ovine et caprine. Les agents pathogènes en cause, le virus de la variole 
ovine (clavelée) et celui de la variole caprine, entraînent respectivement chez les moutons 
et les chèvres une maladie aiguë ou sub-aiguë caractérisée par des lésions de variole 
généralisées sur la peau et les muqueuses, une fièvre persistante, une lymphadénite et 
souvent une pneumonie virale. On retrouve des lésions noduleuses uniformément répartie 
sur les différents lobes des poumons.  
Contre ces deux maladies des petits ruminants il n’existe pour l’instant aucun 
traitement médical curatif. Par conséquent, les seuls moyens efficaces pour leurs 
contrôles sont les mesures de prophylaxies sanitaires et médicales. Les premières, 
nécessitant des actions d’abattage des animaux, de contrôles draconiens des mouvements 
d’animaux, des mises en quarantaine, sont des mesures nécessitant d’importants moyens 
financiers et une très bonne organisation des services vétérinaires, conditions non 
disponibles dans la plupart des pays concernés par ces deux maladies, des pays en 
développement. Aussi dans ces conditions le seul moyen effectif applicable pour limiter 
l’impact négatif de la PPR et de la variole des petits ruminants sur l’économie est la 
vaccination. Il existe des vaccins monovalents efficaces contre chacune de ces deux 
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maladies mais ils sont employés de façon sporadique, généralement, à l’occasion de 
menaces immédiates d’épidémie. La raison probable de cette attitude des services 
vétérinaires des pays concernés est le coût élevé des campagnes de vaccination 
systématique des petits ruminants lié surtout à la logistique importante à mettre en œuvre, 
ce en comparaison du prix unitaire d’un mouton ou d’une chèvre, ce en ne tenant pas 
compte du rôle social joué par ces animaux.  
Pour notre thèse, nous avons mené un travail dont l’objectif était de développer 
des vaccins bivalents qui pourraient contribuer à une baisse du coût des campagnes de 
vaccination contre la PPR et la variole des petits ruminants et thermotolérants, 
caractéristique liée au virus capripox. Pour cela nous avons inséré dans le génome d’une 
souche vaccinale de virus capripox, la souche KS1, l’ADN complémentaire (ADNc) des 
gènes des protéines vaccinantes du virus de la PPR, la protéine de fusion (F) et 
l’hémagglutinine. Les virus capripoxvirus sont très spécifiques de leurs hôtes, les bovins, 
les chèvres et les moutons. Ils ne sont pas pathogènes pour l’homme et constituent ainsi 
un vecteur idéal pour le développement de vaccins recombinants destinés à lutter contre 
les maladies de ruminants. Le présent manuscrit dans lequel nous rapportons les résultats 
que nous avons obtenus est composé de plusieurs parties : d’abord un résumé de l’état 
actuel des connaissances sur la PPR et les varioles des ruminants, ensuite la construction 
du recombinant capripox-FPPR, puis celle du capripox-HPPR, et enfin une comparaison 
des promoteurs poxvirus pour la production de la protéine recombinante H-PPR par le 
virus capripox. Le manuscrit se termine par une conclusion sur l’ensemble de nos travaux 
et d’une réflexion sur les perspectives pour les produits que nous avons développés.  
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Summary 
 
Two highly contagious diseases, Peste des Petits Ruminants and Sheep and Goat 
Pox, constitute main constraints to small ruminants production in many countries in Asia, 
the Near and Middle East and Africa. Peste des Petits Ruminants (PPR), also known in 
the past as goat plague, is a highly contagious viral disease affecting domestic and wild 
small ruminants. It is caused by a virus which belongs to the Morbillivirus genus of 
Paramyxoviridae family: the Peste des Petits Ruminants Virus (PPRV). It is a rinderpest-
like infection of goats and sheep characterized by erosive stomatitis, enteritis, pneumonia 
and death. Economically, it is the most important small ruminant disease in areas where it 
is endemic. In the same regions, there is a second contagious viral disease, Sheep and 
goat pox. The responsible pathogens, the sheeppox virus (SPPV) and goatpox virus 
(GTPV), cause acute to sub acute disease of infected sheep and goats respectively. The 
clinical signs of infection may include generalized pox lesions throughout the skin and 
mucous membranes, persistent fever, lymphadenitis, and often a focal pneumonia and 
nodules lesions distributed uniformly throughout the lungs. 
There is no curative medical treatment against these two viral diseases. Therefore, 
the only way of tackling them is by means of sanitary and medical prophylaxis. Sanitary 
prophylaxis to be effective needs the existence of efficient veterinary services, the 
implementation of animal movement controls with sometimes the stamping out policy. 
The cost needed for the effective implementation of these means in a short period is too 
high for most of countries where these diseases are endemic. Therefore the only way for 
effective control of PPR and sheep and goat pox in those countries is the medical 
prophylaxis, i.e. the vaccination. Currently, efficient attenuated vaccines exist against 
each of these diseases. Unfortunately, in most cases they are used only in face of 
outbreaks to limit their extension. The cost of the logistic needed for systematic 
vaccination campaigns of small ruminants against either PPR or capripox may be too 
high for countries if only the individual economic value of goat or sheep, excluding their 
social value, is considered. A way to cut down this cost is the use of polyvalent vaccine 
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which would enable, in one shot, the protection of animals against more than one 
economic important disease.  
The objective of our thesis work was to develop dual vaccines that could be used 
to protect sheep and goat against both PPR and capripox and also thermostable, a 
characteristic linked to the capripoxvirus, and thereby would contribute to cut down the 
cost of vaccination campaigns. For that, the complementary DNA, cDNA, corresponding 
to the gene of PPRV immune protective proteins, the fusion (F) and the haemagglutinin 
(H) proteins were inserted into the genome of the attenuated strain capripox virus strain 
KS1. Such a recombinant vaccine may be thermotolerant, a characteristic of poxviruses 
and this may improve the quality of the vaccine for its use in hot climate conditions. 
Capripox viruses are highly host-specific microorganisms. They are not pathogenic to 
human and their host range is limited to cattle and small ruminants and possibly 
buffaloes. Therefore they constitute an ideal and safe vector for the development of 
recombinant vaccines for use against ruminant diseases. The present manuscript in which 
we report on the results we have obtained during our thesis work is composed of the 
following different parts: a general introduction, a literature review of PPR and capripox 
viruses, the construction of two recombinant vaccines FPPR/Capripox and 
HPPR/Capripox, the comparison of efficacy of three poxvirus promoters in HPPRV. 
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GENERAL INTRODUCTION 
 
 
In most of developing countries, small ruminant farming allows to cover the basic 
necessities of the majority of peasants. Sheep and goats are an essential source of 
subsistence. They determine the survival of the poor people in these countries. 
Unfortunately, in part of Asia and Africa regions, the production of small ruminants is 
threatened by a highly contagious and fatal disease: the Peste des Petits Ruminants 
(PPR). Another economically important disease is affecting the same regions, the Sheep 
and Goat Pox. Both PPR and Sheep and Goat pox are transboundary diseases; and they 
make part of the group of economic important animal diseases which outbreaks should be 
notified to the World Organisation for Animal Health (OIE for Office International des 
Epizooties). Because of the high importance of sheep and goats for the poor, the control 
of diseases which have a negative impact on their productions is a major goal for 
programmes aimed at poverty alleviation. Live attenuated monovalent homologous 
vaccines are available for the control of PPR and sheep and goat pox. However, the PPR 
vaccine is thermolabile and its application requires strict cold chain. In contrast, the live 
vaccine applied against sheep and goat pox is thermotolerant, inherent property of 
poxviruses. Both vaccines protect after a single injection and the induced immunity 
covers at least the economic life of the animals, around three years. Since both diseases 
are found in the same regions, it could be interesting to use a bivalent vaccine that 
protects against the two infections and this may promote a wider use of vaccination for 
their control. 
To this objective, we have decided to use a live attenuated capripoxvirus as a 
vector for expressing protective antigens from PPR virus. We expected that the resultant 
recombinant would be thermotolerant, a characteristic of poxvirus, and effective in the 
control of both PPR and capripox after a single inoculation to animals. Thereby it is 
intended to reduce the cost of vaccination campaigns. While developing such a vaccine, 
we also conducted a study in order to increase its efficacy by the evaluation of three 
different promoters and the comparison of their capability to induce protective immunity 
against PPR.  
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PESTE DES PETITS RUMINANTS 
Definition & Background 
Peste des petits ruminants (PPR), also known as goat plague, is a highly contagious 
viral disease affecting domestic and wild small ruminants, (Furley et al., 1987). It is 
caused by a virus which belongs to the Morbillivirus genus of family Paramyxoviridae: 
the Peste des Petits Ruminants Virus (PPRV). It is a rinderpest-like infection of goats and 
sheep characterized by erosive stomatitis, enteritis, pneumonia and death. Economically, 
it is the most important small ruminant disease, particularly in areas where it is endemic: 
countries located between the Sahara and the Equator in Africa, the Middle East and the 
Indian sub continent (Lefevre and Diallo, 1990; Taylor et al., 1990; Roeder et al., 1994 
and Amjad et al., 1996). It is in the list of animal diseases to be notified to the World 
Organisation for Animal Health (Office International des Epizooties, OIE) in case of 
outbreaks. 
 
The disease was first described in 1942, in Cote d’Ivoire, by Gargadennec and 
Lalanne (1942). The authors reported on the presence of a highly fatal disease resembling 
to rinderpest but affecting only small ruminants. Cattle in contact with sick animals of 
this contagious disease were not affected. Latter on, in 1956, Mornet and his 
collaborators (1956) showed on experimental animals that the causative agents of 
rinderpest & PPR were closely related. From their experiment, they suggested that the 
second virus was a variant of the first one which is better adapted to small ruminants. 
Other subsequent experiments and studies showed that there were actually two different 
viruses although closely related but evolving independently in nature (Hamdy et al., 
1976; Gibbs et al., 1979; Taylor W.P., 1984; Diallo et al., 1987; 1994). 
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 PPR got different designations in the past, which almost all refer to the clinical 
signs of the disease: erosive stomatitis, goat enteritis, catarrhal fever of goat and Kata 
(Nigerian local name that means catarrh in English). The term goat plague was also used 
due to the reason that the disease was producing high level of mortality in goat 
populations. Finally, the scientific name unanimously adopted is Peste des Petits 
Ruminants (PPR). 
 
Symptoms  
PPR covers three essential forms: a per acute form, an acute form and a mild form.  
 The per-acute form is seen in young goats. The incubation period is of two days 
on average. Then appears a strong hyperthermia (41 – 42 °C) quickly followed by an 
attack of the general state (prostration, pilo-erection, anorexia). The animal shows oral 
and ocular discharges. In the first days of the disease, constipation can appear. This will 
be followed very quickly by profuse diarrhoea. In all cases, the disease leads towards 
death within 5-6 days after the beginning of hyperthermia. The evolution of this per acute 
form is so fast that it does not allow the appearance of other evocative clinical signs of 
the disease. 
 
 The acute form, most characteristically, resembles to rinderpest. The incubation 
period is three to four days and the first clinical signs are identical to those of the per-
acute form although they are less intense. The disease develops over a longer period. This 
allows the appearance of other symptoms absent in the preceding form: thus the 
congestive lesions of the oral mucosal membrane are replaced by ulcers covered by white 
necrotic tissues (Figure 1). The pulmonary sign is manifested by dry cough, which 
quickly becomes purulent. The ocular and nasal discharges are serous at the beginning 
and later on, become mucopurulent. Breathing becomes difficult because of the 
pulmonary attack (broncho-pneumonia) and the partial nasal obstruction by thick 
mucosal secretions (Figure 1). These signs are in fact the results of bacterial 
complications, generally by infection with Pasteurella multocida. Because of this form, 
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PPR was for a very long time confused with pasteurellosis. Other complications of 
parasitical origin, such as coccidiosis, can render difficult the clinical diagnosis. Pregnant 
females abort in most cases. The evolution of the disease ends most often by death (40 - 
60 %). Those animals surviving the disease remain immunized for the rest of their life. 
 
The mild forms are much more frequent than the previous ones and very often 
they are undetected clinically and are discovery of serosurveillance (Scott, 1981). At the 
moment of infection animals may have a slight and temporary hyperthermia. Sometimes 
less abundant ocular and nasal discharges may appear. Dried-up purulent discharges 
around the nostrils of the animal can be observed and this symptom may lead to 
confusion with the contagious ecthyma.  
 
Up to 100% of the animals may be affected by PPR in a flock and the mortality 
rate may range from 0 to 90% according to a) the animal age, young animals over 3 
months of age are no longer protected by colostral antibodies anti PPR being highly 
susceptible to the infection, while old animals which have survived from precedent 
outbreaks are protected life long, b) the breed, dwarf goats seem to be more affected than 
sahelian breeds, and c) the species,  some findings indicate that sheep are more resistant 
than goats and others claim the opposite (Shaila et al., 1989; 1996b; Lefèvre P.C. and 
Diallo A., 1990; Taylor et al., 2002; Diallo A., 2003).  For the moment, no study has 
shown a clear difference in virulence between virus strains so far isolated (Diallo A., 
2003). 
 
The carcass of an animal which has died from PPR infection is usually emaciated, 
the hindquarters soiled with soft/watery faeces and the eyeballs sunken. The eyes and 
nose contain dried-up discharges and the signs and lesions due to PPRV are listed in the 
Table 1. 
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Location Signs and symptoms 
Eye Profuse catarrhal conjunctivitis, discharges in 
advanced PPR infection. 
Nose Serous nasal discharge at the beginning, then 
becoming mucopurulent eroded yellow 
exudates, partial blockage of the nostrils by 
dried-up purulent discharges, Small erosions 
and petechiae 
Mouth Eroded and dead cell on the gums, obscured 
membrane and nodular lesions. 
Lips  Swollen, oedematous, and erosive stomatitis 
involving the inside of the lower lips. 
Respiratory 
tract 
Small erosions and petechiae on the nasal 
mucosa, turbinates, larynx and trachea 
Lungs Small, dark red/purple areas, firm to the 
touch, in the anterior and cardiac lobes of the 
lungs. 
Small intestine Congested, eroded and haemorrhagic. 
Large intestine Congested, in the form of Zebra stripes in the 
posterior part of the colon. 
Lymph nodes Enlarged and oedematous.  
 
Table 1: Classical signs and lesions of PPRV infection. 
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A                                                                                 B 
Figure 1: Illustration of clinical signs induced by peste des petits ruminants. 
Classical Mucopurulent nasal and mouth discharge (A); Erosive stomatitis with dead cells on 
the gums involving the inside of the lower lip (B) 
 
Aetiologic agent and its structure. 
The virus which causes PPR belongs to the Morbillivirus genus of the 
Paramyxoviridae family. It is closely related to the rinderpest virus, the measles virus of 
humans, the distemper virus of dogs and some wild carnivores, and the morbilliviruses of 
aquatic mammals. As all members of the family Paramyxoviridae, PPRV is an enveloped 
pleomorphic particle whose diameter varies between 150 and 700 nm, with a mean of 
500 nm. For the rinderpest virus particles, this mean size is around 300 nm (Durojaiye et 
al., 1985; Bourdin P. and Laurent-Vautier A., 1967). This size variation may be linked to 
the number of nucleocapsids incorporated into the virus particles. In the case of measles 
virus, this number might be more than thirty (Rager et al., 2002). The nucleocapsid is 
formed by the viral genomic RNA, a single-stranded RNA of negative sense, wrapped by 
the nucleoprotein (N) to which are associated two other viral proteins: the phosphoprotein 
(P) and the RNA polymerase (L for large protein). It appears as a tube which is long of 
about 1 µm with a diameter of around 18 nm (Bourdin P. and Laurent-Vautier A., 1967; 
Gibbs et al., 1979). From the envelope protrude spikes formed by the two viral 
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glycoproteins which are essential in the first steps of the host cell infection by the virus, 
the haemagglutinin (H) and the fusion (F) proteins (Diallo, A., 1990).  
Viral structural proteins.  
- The Nucleocapsid (N) protein 
The N protein is the major viral structural protein of morbilliviruses. They 
migrate on polyacrylamide gels with an apparent molecular weight ranging from 60 for 
PPRV to 68 kDa for RPV (Diallo et al., 1987). For the latter case, the high apparent MW 
seems to be linked to the phosphorylation of the protein. No biological significance has 
been attributed yet to this post-translation modification of RPV N protein. However, for 
the rabies virus (RV), member of the family Rhabdoviridae, both RNA transcription and 
replication are reduced if the N protein is not phosphorylated (Wu et al., 2002; Yang et 
al., 1999). Sequence data are now available for all the morbillivirus N proteins. They 
consist of 525 amino acid residues for RPV, MV and PPRV but only 523 amino acids in 
the case of CDV, PDV, DMV and PMV (see review in Diallo A., 2003). Sequence 
comparison of the different N proteins reveals amino acid identities varying from 67 to 
74% between the different morbilliviruses. Protein sequence has allowed the 
identification of four regions with different degrees of conservation: region I (amino acid 
residues 1 to 120) is quite well conserved with 75–83 % identity across the group, region 
II (amino acid residues 122–145) shows only a low sequence identity at about 40%, 
region III (amino acid residues 146–398) is the most conserved with 85 to 90% identity 
and finally region IV, which is the C-terminal fragment (amino acids 421–523/525), the 
least conserved part of the protein with about 17 to 30% of homology (Diallo et al., 
1994). The nascent N protein when expressed alone, either in mammalian, insect or 
bacterial cells, quickly associates into nucleocapsid-like aggregates to form a more 
condensed form of the protein (Mitra-Kaushik et al., 2001). These N-protein aggregates 
can be detected in both the cytoplasm and the nucleus of the transfected cells. The signal 
required for nuclear transport (NLS) has been attributed to the leucine/isoleucine-rich 
motif (TGILISIL) at positions 70-77 of CDV N sequence (Yoshida et al. 1999; Sato et 
al., 2006). At the same position, the N sequence of the attenuated PPRV 75/1 strain is 
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TGVMISML. The replacement of 3 leucine/isoleucine residues by other amino-acids has 
probably altered the NLS motif in the PPRV 75/1 N since this protein is never found in 
the nucleus (A. Diallo, unpublished data). 
- The Phosphoprotein (P) Protein.  
P is one of the three protein components of the Ribonucleoprotein (RNP) and acts 
as a co-factor for the RNA-dependent RNA-polymerase (RdRp). It is a multifunctional 
protein, which binds both the N and L proteins and acts as a chaperone to keep the N in a 
soluble form for binding to the RNA. The P proteins are much smaller (54–55 kDa) than 
the values determined from polyacrylamide gels where they migrate at 72–86 Kd (Diallo 
et al., 1987; Bolt et al., 1995). This aberrant migration can be attributed to the post-
translational phosphorylation of the protein which is rich in serine and threonine. PPRV 
has the longest P protein with 509 amino acids while the DMV P is the shortest with 506 
amino acids. MV, RPV, CDV and PDV all have P proteins of 507 amino acids. P is one 
of the least conserved virus proteins, RPV and PPRV sharing only 51.4% amino acid 
identity (Mahapatra et al., 2003) with the region extending from position 21 to 306 
containing many unconserved residues. Of the three serine residues (positions 38, 49, and 
151) identified as potential phosphorylation sites in the RPV P protein, only Ser151 is 
conserved in all morbilliviruses (Kaushik and Shaila, 2004). The C-terminal region of 
paramyxovirus P proteins contains the domain that interacts with the exposed C-terminus 
of the N protein (Ryan and Portner, 1990; Huber et al., 1991). Harty and Palese (1995) 
have mapped the N binding sites of MV P to two regions: one is present in the N-terminal 
100 amino acids, the other being more precisely defined as residues 459–507 at the C-
terminus. Using the yeast two-hybrid system it was shown that an N-terminal 60 amino 
acid region and a C-terminal amino acid region (316–346) are simultaneously involved in 
an N-P interaction in RPV (Shaji and Shaila, 1999). A more distant C-terminal region of 
the P protein interacts with L protein in the case of SeV (Smallwood et al., 1994). 
Furthermore, reflecting the fact that this region has important functions, the C-terminal 
half of P is more conserved than the N-terminal half, residues 311–418 being the most 
conserved. The active form of P protein is a tetramer and oligomerization of the protein 
rather than its phosphorylation, as previously suggested (Kaushik and Shaila, 2004), is 
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absolutely required for its replication/transcription activity in the RdRp complex in vitro 
(Rahaman et al., 2004). Interestingly, the N protein of most morbilliviruses is found both 
in the cytoplasm and in the nucleus, but when complexed with the P protein, it is found 
exclusively in the cytoplasm (Huber et al., 1991; Gombart et al., 1993). The biological 
significance of this finding remains unknown. 
 
- The Matrix (M) protein  
The M protein is located inside the viral envelope and is the most conserved protein 
within the group with identities ranging from 91%, between CDV and PDV, to 76%, 
between RPV and PDV/CDV, while RPV and PPRV share 84% identity (Table 2). Only 
a stretch of 20 residues lying between positions 195 and 214 varies significantly between 
morbilliviruses (Haffar et al., 1999). A pivotal role is played by M protein in the 
formation and release of paramyxoviruses particles as it serves as a bridge between the 
external surface viral glycoproteins (H and F) and the nucleocapsid (for review, see 
Peeples, 1991; Coronel et al., 1999; 2001). It is well established that epithelial cells are 
polarized, having distinct apical and basolateral domains which are different in structure, 
for example in lipid and protein composition, and possibly function (Rodriguez and 
Nelson, 1989). It has been shown with MV that maturation and release of virus particles 
occur at the apical surface of epithelial cells although the two viral glycoproteins are 
found mainly at the basolateral surface (Blau and Compans, 1995; Maisner et al., 1998; 
Naim et al., 2000; Moll et al., 2001; Riedl et al., 2002). The M protein is known to direct 
to the apical surface of polarized cells the viral glycoproteins which otherwise would 
accumulate on basolateral surfaces due to a tyrosine-dependent sorting signal located in 
their cytoplasmic tails. MV viruses bearing a tyrosine point mutation in this sorting signal 
are unable to propagate by formation of syncytia in polarized cells in vitro and in vivo 
(Moll et al., 2004). Blood cells such as macrophages which disseminate the virus in the 
host are likely to be infected upon contact with the basal surface of epithelial cells by 
direct cell–cell fusion, which is an alternative way for MV to infect cells (Naim et al., 
2000; Moll et al., 2001). 
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- The Fusion (F) protein 
The morbilliviruses produce two surface glycoproteins which are embedded in the 
viral envelope and protrude as spikes: the fusion (F) and the Haemagglutinin (H) 
proteins. F enables the virus to penetrate the host cell by mediating the fusion of the viral 
and cellular membranes at neutral pH. For this process to occur, cooperation with the H 
protein is required since this protein acts in promoting the activity of F (Moll et al., 2002; 
Plemper et al., 2002). The F gene of all morbilliviruses consists of about 2200 to 2400 
nucleotides depending on the virus, 2410 for PPRV F gene. One interesting feature which 
characterises morbillivirus F mRNAs is the existence of a long 5’-untranslated region 
(UTR), which is 580 nucleotides long for MV but 634 for PPRV.  
The morbillivirus F mRNA translated product, named F0, is composed of 537–552 amino 
acids residues depending on the virus. Alignment of the F0 from different morbilliviruses 
reveals high conservation along the whole length of the protein sequence apart from two 
variable hydrophobic domains (Evans et al., 1994; Meyer and Diallo, 1995). The first is 
located near the N-terminus and ends at the conserved motif QIHW. This hydrophobic 
region is predicted to be the signal peptide sequence required for directing the protein 
through the rough endoplasmic reticulum (RER) and the Golgi apparatus. It is removed 
by cellular endoproteases after its transfer of the protein to the cell surface. Without the 
signal sequence all mature morbillivirus F proteins consist of 527 amino acids. The 
second variable region is located towards the C-terminus and is predicted to anchor the 
protein into the membrane: the only requirement for this function appears to be that their 
sequences are hydrophobic in nature. This leaves the extreme C-terminus on the 
cytoplasmic side of the membrane where it can interact with the M protein. This 
orientation in the membrane with a C-proximal anchor and a N-proximal ectodomain 
classifies the F as a type I glycoprotein. 
 
 The fusion domain is the third hydrophobic domain in the F protein but, unlike 
the other two, is highly conserved in all paramyxoviruses. F0 is the inactive form of F. It 
is activated only upon a proteolytic cleavage to give two sub-units F1 and F2 which 
remain linked to each other by disulphide bonds. This places the hydrophobic fusion 
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domain at the N-terminus of the F1 protein. Cleavage of F0 is not required for virus 
assembly but is critical for the infectivity and pathogenesis in all paramyxoviruses 
(Watanabe et al., 1995a). For morbilliviruses, cleavage of F0 occurs at the carboxyl side 
of the pentapeptide Arg-Arg-X1-X2-Arg (X1 being any amino acid but X2 must be either 
arginine or lysine). This sequence conforms to the minimal consensus sequence Arg-X-
X-Arg recognized by furin, an endopeptidase which is present in the trans-Golgi network 
(Watanabe et al., 1995b). 
- The Haemagglutinin (H) protein 
The H protein enables the virus to bind to the cell receptors, the main being the 
signalling lymphocyte activation molecule (SLAM also called CD 150), a cell membrane 
glycoprotein of the immunoglobulin superfamily (Tatsuo et al., 2001). H cooperates with 
F for the fusion activity of this latter protein (Wild et al., 1991; Das et al., 2000). The H 
protein varies in length from 604 amino acids for DMV to 617 amino acids for MV while 
the RPV and PPRV H proteins have 609 amino acid residues. It has only one long 
hydrophobic domain near the N-terminus (positions 35–58), which acts as a signal 
peptide but, unlike the signal peptide in the F protein, it is not cleaved from the mature 
protein as it also functions to anchor the protein in the membrane. The N-terminal 34 
amino acids remain on the cytoplasmic side of the membrane while the C-terminus is 
extruded to the outside. This arrangement, with a N-terminal anchor and a C-terminal 
external domain, classifies H as a type II glycoprotein. The mature protein is a 
disulphide-linked homodimer, which probably associates into tetramers in the spike 
(Plemper et al., 2000; Vongpunsawad et al., 2004). Like the F protein, maturation of H 
protein occurs by glycosylation, folding and oligomerization as it passes through the RER 
and the Golgi complex before reaching the cell surface (Hu et al., 1994; Blain et al., 
1995; Plemper et al., 2001). The folding is mediated through a transient association of H 
with cellular chaperone proteins such as calnexin and GRP78 and misfolding of the MV 
H may result from its retention by the chaperones in the RER and inefficient migration to 
the cell surface (Bolt, 2001). Reduced transport of the H protein to the cell surface where 
it can interact with the F protein impairs its capacity to mediate cell-cell fusion (Plemper 
et al., 2000). Critical cysteine residues at positions 139 and 154 in H-MV were identified 
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as responsible for its reduced H dimerization and migration to the cell surface. 
Oligosaccharide side chains are added to the polypeptide in the lumen of the RER, the 
number of potential N-glycosylation sites on H varying between viruses and within each 
virus. These side chains are required to move the protein along the exocytic pathway to 
the cell membrane and the degree of glycosylation may influence the antigenicity of the 
molecule (Hu et al., 1994). It was shown for the haemagglutinin-neuraminidase (HN) 
protein of Newcastle Disease virus (NDV) (Panda et al., 2004) that the degree of 
glycosylation may affect the virus virulence.  This has not yet been demonstrated for 
morbilliviruses. 
The H protein, like the P protein, is not well conserved in morbilliviruses. The most 
distantly related viruses, RPV and PDV, share only 32% amino acid identity and this only 
rises to about 50% when the two ruminant morbilliviruses, RPV and PPR, are compared 
(Table 2). This high degree of sequence variation most probably reflects the role of H in 
binding to host cell receptor(s) and this means that it is also the main target of the host 
humoral immune responses and virus neutralizing antibody responses are mainly directed 
against the H protein. For MV, it has been shown that amino acid changes in H that are 
potentially linked to the host’s adaptive evolution are located in B-cell epitopes and at sites 
linked to its interactions with the cell receptor (Lecouturier et al., 1996; Hsu et al., 1998). 
B-cell epitopes capable of inducing neutralizing antibodies have been mapped on the H 
protein to exposed β-sheets on the proposed three-dimensional structure (Langedijk et al., 
1997; Sugiyama et al., 2002). Recombination by reverse genetics has shown that, while the 
H proteins of MV and CDV are interchangeable (Nussbaum et al., 1995; Stern et al., 1995; 
von Messling et al., 2001), those of RPV and PPRV are not (Das et al., 2000). A number of 
paramyxovirus glycoproteins have been shown to have both haemagglutinating and 
neuraminidase activities. However, for the morbilliviruses, strains of MV adapted to grow 
in tissue culture were the only example within the genus to have haemagglutinating 
activity, amino acid residues at positions 451 and 481 being critical for the maintenance of 
this activity (Lecouturier et al., 1996). Some studies have shown that PPRV also has 
haemagglutination capabilities (Wosu, L., 1985; 1991; Seth and Shaila, 2001). PPRV 
seems to be the only morbillivirus whose H protein resembles to the haemagglutinin-
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neuraminidase (HN) protein of viruses of the Paramyxovirus genera as it has also 
neuraminidase activity (Langedijk et al., 1997; Seth and Shaila, 2001). The RPV H protein 
has been shown to have limited neuraminidase activity but it cannot agglutinate red blood 
cells (Langedijk et al., 1997). 
- The Large (L) protein 
The RdRp (L protein) is the largest virus protein and is also the least abundant. It 
migrates with an apparent molecular weight of about 200 kDa and is composed of 2183 
amino acids for MV, RPV, PPRV and cetacean morbillivirus but 2184 for CDV and PDV 
(Rima et al., 1986; 2005; Baron MD and Barrett T., 1995; McIlhatton et al., 1997; Martha 
Y., 2001; Muthuchelvan et al., 2005; Bailey et al., 2005). Considering the size of the L 
protein, it is surprisingly conserved between morbilliviruses, the percentage identity 
between the L proteins of RPV and PPRV being about 83% as shown in table 2. CDV and 
PDV L proteins share the highest percentage of homology with 89.7% of amino acids in 
common while PPRV L and CDV L share only 57% (Bailey et al., 2005). Comparison of 
the L protein sequences of morbilliviruses identified three relatively conserved domains 
separated by less conserved ‘hinge regions’ (McIlhatton et al., 1997). By the reverse 
genetics technology, foreign gene like the functional green fluorescent protein (GFP) has 
been inserted into the L protein at the second hinge region for both MV and RPV but 
attempts to introduce foreign sequence at the first hinge failed (Duprex et al., 2002). 
Insertion of the GFP ORF in frame with the L protein sequence produces a green 
fluorescent virus which grows to an equivalent titre to that of the parent virus in Vero cells; 
however, this insertion greatly attenuates the RPV pathogenicity for cattle (Brown et al., 
2005a). 
Because of its size, the RdRp is assumed to carry all the activities necessary for 
genomic RNA replication and transcription into functional mRNA. All deletion/site 
mutation studies carried out so far on the protein of different non-segmented negative-sense 
RNA viruses indicate that the three conserved domains perform functions of the protein 
(Malur et al., 2002; Cartee et al., 2003). The first domain, residues 1 to 606, has the 
sequence KEXXRLXXKMXXKM at position 535–549, which is thought to be the RNA 
binding motif. The second domain, residues 650–1694, contains the sequence GDDD, 
 29 
flanked by hydrophobic regions, which is thought to be the functional polymerase site of 
RdRp while the third domain, residues 1717–2183, has kinase activity and may also act as 
an ATP binding site (Blumberg et al., 1988). 
The L protein can only function as an RdRp when it is associated with its 
cofactor, the P protein. Horikami et al. (1994) mapped the binding site for the P protein 
of MV to the N-terminal 408 amino acids of the L protein, part of domain I. The 
sequence ILYPEVHLDSPIV, at positions 9 to 21 of morbillivirus L proteins, is partially 
conserved within the Paramyxoviridae family and mutations/deletions involving the 
sequence ILYPE reduces the binding of P protein to the human parainfluenza virus type 3 
(hPIV3) L protein and also reduces its transcription function (Malur et al., 2002). 
Virus non-structural proteins 
- The C protein 
In addition to the six structural proteins mentioned here above, paramyxoviruses 
can also produce a range of non-structural proteins in infected cells. These are encoded 
by the P transcription unit in alternative reading frames. The first of these, the C protein, 
is generated by translation of the P mRNA from another open reading frame (ORF) 
different from the one encoding P protein by use of a second initiation AUG codon which 
in the case of PPRV, RPV and RPDV, is at 19 nucleotides downstream from the first. 
This second initiation codon is accessed by skipping the first one due to leaky scanning 
as neither of these first two AUG codons (CCGAUGG and ACCAUGU, respectively) is 
in an ideal Kozak context (Kozak, M. 1986). The C protein is a small basic protein with a 
molecular weight of 19–21 kDa. For both RPV and PPRV it is composed of 177 amino 
acids, three residues longer than those of CDV and PDV (Barret et al., 1985; Curran, 
M.D. and B. Rima, 1992; Baron et al., 1993). The MV C protein with 186 amino acids is 
the longest whilst DMV, with only 160 amino acid residues, is the shortest (Bellini et al., 
1985; Bolt et al., 1995). Sequence alignment reveals a high degree of conservation 
between the different morbillivirus C proteins at the C-terminus (Mahapatra et al., 2003). 
While the P protein is phosphorylated and found only in the cytoplasm in association 
with the nucleocapsids, the C is not phosphorylated and can be detected in both the 
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nuclear and cytoplamic compartments of MV infected cells (Bellini et al., 1985; Alkhatib 
et al., 1988). However, RPV C protein is uniformly distributed into the cytoplasm and is 
not found in the nucleus (Sweetman et al., 2001). Interactions of the morbillivirus C 
proteins with other virus proteins have been studied but the results are not consistent. The 
RPV C protein self interacts as well as binds to the L protein (Sweetman et al., 2001), 
indicating a function in modulation of RdRp activity. Other workers could not 
demonstrate an interaction either with itself or with any of the other viral proteins in MV 
infections (Liston et al., 1995). As the C protein has an unusual high isoelectric point, 
creating a strong positive charge at physiological pH, a possible interaction with RNA 
has been suggested (Radecke and Billeter, 1996). C functions are very poorly understood 
in terms of their biological significance, although there is evidence that C is a virulence 
factor for MV (Patterson et al., 2000). Using reverse genetics techniques it has been 
possible to produce viruses that do not express protein C and MV C-minus mutants show 
no reduction in viral multiplication nor in the formation of progeny virus in Vero cells. 
However, they produce reduced number of progeny virus in human peripheral blood 
mononuclear cells, a normal target cell for MV (Radecke and Billeter, 1996; Escoffier et 
al., 1999). A RPV C knockout virus, however, showed impaired growth in Vero cells 
together with reduced viral RNA synthesis (Baron and Barrett, 2000). SeV C-minus 
mutants show impaired viral replication in vivo (Tapparel et al., 1997) and prevention of 
expression of all the four variants of the C protein in this virus results in severe 
attenuation of growth in tissue culture and the abrogation of pathogenicity in the natural 
host (Kurotani et al., 1998). Thus C seems to act as virus virulence factor and in the case 
of MV it was shown to be an interferon antagonist (Shaffer et al., 2003). Another 
function of C protein as infectivity factor might be to stabilize virus particles and 
therefore sustains the viral infection. It is therefore necessary for the efficient virus 
replication (Devaux P and Cattaneo R., 2004; Takeuchi et al., 2005; Von Messling et al., 
2006).  
- The V protein 
This protein is translated from a mRNA produced from the P gene by addition of 
one or more non-template G residues, depending on the paramyxovirus, during the 
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transcription process. For all morbilliviruses, there is only one extra G insertion at 
postion 752 in a highly conserved site (5’UUAAAAAGGGCACAG) named editing site 
(Baron et al., 1993; Blixenkronemoller et al., 1992; Cattaneo et al., 1989; Mahapatra et 
al., 2003). This non-template G residue addition in the mRNA results in a frame shift of 
the open reading frame after the extra nucleotide insertion point. As a result, V is shorter 
than P. Both have an identical N-terminal but different C-terminal protein sequences. For 
PPRV, V is composed of 298 amino acid residues with a predicted molecular mass of 
32.3 kDa. It is one amino acid shorter in length than the corresponding proteins of CDV, 
PDV, RPV and MV, whereas DMV has the longest V protein (303 amino acids) of all 
morbilliviruses (Mahapatra et al., 2003). The RPV V protein is phosphorylated and like 
P, can bind to both N and L, indicating involvement of this protein in the regulation of 
viral RNA synthesis (Sweetman et al., 2001). V has also been shown to bind 
unassembled N, but not encapsidated N of other paramyxoviruses (Watanabe et al., 1996; 
Horikami et al., 1996; Randall and Bermingham, 1996). This means V may bind to N to 
keep it soluble prior to encapsidation as suggested ealier by Precious et al. (1995). 
Similar studies with MV using the yeast two-hybrid system, failed to show a V–N 
interaction (Liston et al., 1995). These discrepancies may be due to the insensitivity of 
the systems used for detecting protein–protein interactions. The C-terminal region of V 
protein is highly conserved among morbilliviruses and nine amino acids are shared at the 
editing site, including seven highly conserved cysteine residues. These, along with a 
number of other residues, are conserved in all paramyxoviruses wherever V protein 
expression has been shown. This arrangement of cysteines at the C-terminus of V is 
similar to motifs found in metal ion-binding protein and, in fact, this domain of MV and 
the Simina virus 5 (SV5) V proteins has been shown experimentally to bind to zinc ions 
(Liston and Briedis, 1994; Paterson et al., 1995). It has also been reported that the 
cysteine-rich motif interacts with a host cell-derived protein, the 127 kDa subunit of the 
damage-specific DNA binding protein (DDB1) (Lin et al., 1998), although the 
significance of these interactions for the function of the V protein is not clear. 
The presumed role of V in regulating RNA synthesis has been studied by abolishing its 
expression after alteration the editing site of the virus, mutation not affecting the P protein 
expression. SeV lacking V grows to a comparable titre, and with a similar phenotype, to 
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wild-type virus in tissue culture cells (Delenda et al., 1997) but displays attenuated 
replication and pathogenesis in mice (Kato et al., 1997). Mutant of RPV and MV lacking V 
are also viable in tissue culture (Schneider et al., 1997; Baron and Barrett, 2000). The 
absence of the V protein enhances viral replication in MV while over-expression attenuates 
RNA synthesis (Tober et al., 1998) indicating a regulatory role of V protein in the 
transcription process. However, in vivo studies with the MV V-minus mutant showed 
reduced RNA synthesis and a reduced viral load in a mouse model with a consequent 
reduction in pathogenicity (Patterson et al., 2000). Baron and Barrett (2000) also reported 
in vitro an enhanced synthesis of RPV genome and antigenome RNAs in a V-minus mutant 
of the vaccine virus but no studies have yet been carried out to establish the role of V in 
pathogenesis. It is demonstrated now that V protein is a highly inhibitor of interferon 
actions and thereby contributes to the immunosuppression induced by morbillivirus 
infections (Palosaari et al., 2003; Takeuchi et al., 2003; Ohno et al., 2004; von Messling et 
al., 2006; Nanda SK and Baron MD, 2006).  
 
 
Virus 
 
Genome  
 
N P C V M F H L 
Peste des 
petits 
ruminants 
 
 
66.98  
 
79.66 58.65 54.02 54.61 89.82 82.74 59.14 83.44 
Measles 
 
70.50  
 
82.70 65.35 65.34 64.55 92.26 85.98 67.33 87.73 
Canine 
distemper 
 
63.58  
 
75.38 53.57 52.91 44.67 83.93 78.75 46.26 81.05 
Dolphin 
morbillivirus 
 
65.91  
 
79.69 57.91 55.29 50.50 89.29 84.52 57.14 83.29 
 
Table 2: Percentage similarity of the RPV Kabete ‘O’ strain to other morbilliviruses 
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Genome 
The genome of morbilliviruses is a single-stranded RNA of negative sense. Its 
entire sequence has been determined for nearly all of them. PPRV has the longest 
genome with 15948 nucleotides while that of CDV, composed of 15702 residues, is the 
shortest (Barrett et al., 2006). For all morbilliviruses, as for many paramyxoviruses, the 
number of nucleotides composing the entire genome is in agreement with the so-called 
“rule of six” (Calain and Roux, 1993; see review by Kolakofsky et al., 1998). This rule 
reflects the fact that each N protein molecule associates with exactly 6 nucleotides of the 
genomic RNA. This latter should be entirely encapsidated by N for its efficient 
transcription/replication. The physical map of morbillivirus genome is similar to that of 
respiroviruses and henipaviruses (see figure 2). It is organised into six contiguous, non-
overlapping transcription units corresponding to the gene of the six structural viral 
proteins in the order of 3'-N-P-M-F-H-L-5' in the genome sense (Rima et al., 1986; Sidhu 
et al., 1993). They are separated by short sequences of three nucleotides called intergenic 
regions (IG) which is CTT in most cases. In some virus strains the H-L junction sequence 
is CGT (Crowley et al., 1988; Baron MD and Barrett T., 1995). Each transcription unit 
starts by the AGGA sequence (AGGG for the F gene) and ends by a stretch of at least 
four (A)s that will serves as a signal for the mRNA polyadenylation by the polymerase in 
a “slippage” manner. At each end of the genome, there is a short sequence of 52 and 37 
nucleotides (but 38 for CDV and PDV) respectively at 3’ and 5’ ends and named leader 
for 3’ end, and trailer for 5’ end. The L-trailer junction sequence is CTT for RPV and 
MV, CTA for PPRV and CAA for DMV, CDV and PDV. The main feature of the 
genome organisation that is unique to morbilliviruses is the existence of a long 
untranslated region (UTR) at 3’ end of M gene and at the 5’ end of F gene (Meyer G. and 
Diallo A., 1995; Haffar et al., 1999). Both regions, in combination with the IG separating 
the two genes, make up a continuous untranslated fragment of about 1Kb of nucleotides 
long with high GC content. It has been shown that these long UTRs are not essential for 
the virus replication. However, they act as modulators of M and F productions to increase 
the replication of the virus but minimize its cytopathogenicity at the same time (Evans et 
al., 1990; Cathomen et al., 1995; Takeda et al., 2005). It is speculated that reduction of 
 34 
the cytopathogenicity may be advantageous for the fitness and the survival of virus in 
nature. 
 
 
Figure 1 
 
Figure 2: Genome organization of representative members of each genus of the 
family Paramyxoviridae. For some members of the pneumoviruses, the M2 and L ORFs 
overlap. Gaps between each ORF are also shown although not to scale. Each ORF is denoted by 
an abbreviation for the protein as detailed in the text. For the rubulaviruses and the 
pneumoviruses and metapneumoviruses as SH (small hydrophobic) gene is present. The 
pneumoviruses also have separate NS (non-structural) genes located upstream of the N protein 
gene. (from Barrett et al., 2006.) 
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Transcription 
Transcription of the genomic RNA by the viral RdRp starts after the release of the 
nucleocapsid into the cytoplasm following fusion of the virus envelope with the cell 
membrane. How the RdRp accesses the template RNA is unclear since the association of 
the nucleocapsid protein with the RNA is intimately strong; it can resist even the high salt 
conditions required for caesium chloride (CsCl) density gradient purification. Access is 
thought to be made possible either by a reversible transition in the protein-RNA 
association or by local displacement of N during transcription, as it occurs in the 
separation of the two strands of DNA during its transcription (for review, see Kolakofsky 
et al., 1998).   
For negative RNA viruses, to synthesize RNA the RdRp can attach to the 
genomic RNA only at the level of the genome promoter (GP) which is formed by the 
leader and the sequence corresponding to the 5’ untranslated region of the N protein 
mRNA (Tapparel et al., 1998; Whelan and Wertz, 1999; Mioulet et al., 2001; Whelan et 
al., 2004). From there, transcription begins and the RdRp proceeds sequentially along the 
genomic RNA in a ‘stop–start’ mode, each transcription unit being defined by the 
trinucleotide intergenic motif (IG) which is not transcribed normally as it serves as a stop 
signal. A non recognition of this signal during the transcription step will result in the 
production of polycistronic mRNAs which contain the IG sequence (for review, see A. 
Banerjee, 1987; Horikami SM and Moyer SA, 1995). In transcription mode, access of the 
RdRp to the downstream transcription unit is therefore entirely dependent upon 
completion and release of a newly synthesized copy of the mRNA from the preceding 
unit. If the RdRp becomes detached from the RNP template during transcription it must 
return again to the GP to reinitiate mRNA synthesis. This leads to a transcriptional 
gradient where less mRNA is transcribed when the gene is more distant from the GP. A 
progressive decline in synthesis of mRNA occurred with a 20–30% loss of transcription 
efficacy across each gene junction as it has been shown experimentally with VSV where, 
using reverse genetics, the positions of the transcription units along the genome were 
changed relative to the GP (Wertz et al., 1998, Wertz and Ball, 2002). This is probably a 
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way for the virus of controlling the amount of each protein produced. It results in the 
higher expression of the N protein, the most abundant protein in virions, and the lower 
production of the L protein (RdRp) which is only required in catalytic amounts. 
All mRNAs are synthesized as naked RNAs and are capped at their 5’ ends and 
polyadenylated at their 3’ ends by the virus encoded polymerase so they are stable and 
efficiently translated by the cell ribosomes. Experiments carried out with VSV showed 
that the conserved trinucleotide (AGG) at the start of the mRNAs is critical for efficient 
gene expression and contains essential signals for the correct processing of the nascent 
mRNA. In its absence, the majority of transcripts are prematurely terminated (Stillman et 
al., 1998, 1999). In addition, this conserved trinucleotide probably forms part of the 
signal for capping and methylation of the mRNAs. The conserved tract of four U 
residues, which always precedes the IG, signals the polyadenylation of the mRNA 
transcripts. These U-rich sequences are integral to the polyadenylation signal and are the 
point where ‘stuttering’ of the RdRp allows hundreds of A residues to be added to the 
ends of mRNAs. This polyadenylation signal may have other functions, at least in VSV, 
as it does not only indicate the end of the upstream mRNA, but also appears necessary for 
efficient transcription of the downstream transcription unit (Hinzman et al., 2002). 
Replication 
At some point after infection, the viral RdRp starts the genome replication. This 
occurs probably through a conformation change induced by the attachment of N on the 
leader sequence of RNA under synthesis, the RNA polymerase doesn’t recognize the 
stop signal of IG. This will result in the synthesis of full copy of genomic to 
antigenomic RNA or full-length RNA of positive sense (for review, see A. Banerjee, 
1987; Horikami SM and Moyer SA, 1995; Whelan et al. 2004). The trailer and the 
3’untranslated region of the L protein together resemble to the genomic promoter. 
They form the antigenomic promoter (AGP). The antigenomic RNA, like the negative 
sense genome RNA, is always encapsidated by the N protein since both the GP and 
AGP sequences contain RNA encapsidation signals. As a consequence, synthesis of 
full-length antigenome RNA and N protein production must be linked (Gubbay et al., 
2001). Therefore, for the replication process association of three viral proteins namely 
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P, L an N are absolutely required. Although morbilliviruses are closely related and that 
both N and L are highly conserved within the group, a study has showed that RNA 
synthesis is efficient only when the three proteins N/P/L come from the same origin, 
either RPV, or MV or CDV (Brown et al., 2005b). The precise mechanism triggering 
the switch from the transcriptive to the replicative mode is not clearly understood. 
However while GP serves for both the transcription and the replication of the genomic 
RNA, AGP is not bi-functional since it is exclusively used by the RNA polymerase for 
the replication of the antigenomic RNA into the genome, the negative sense RNA 
(Whelan S.P.J and Wertz G., 1999; Tapparel and Roux, 1996; Tapparel et al., 1998; 
Mioulet et al., 2001; Whelan et al., 2004). The transition from transcription to the 
replication process by RdRP is still on debate. In the 80’s, a self-regulatory model was 
proposed (Blumberg and Kolakofsky, 1981; for review see Banerjee, 1987). In this 
model, which was widely accepted for many years, the accumulation of unassembled 
N proteins would play the major role in switching the RdRp between its transcriptase 
and replicase functions. This model envisaged a mechanism whereby the RdRp starts 
transcribing the RNP into mRNA and in presence of sufficient amount of N protein 
molecules which bound to newly formed RNA, the RdRp switches to the production 
of a full antigenome RNA. In more details, owing to the absence of sufficient N for 
binding nascent RNA, RdRp recognizes the transcription control sequences at the 
leader–N junction, releases the leader and initiates the synthesis of N mRNA. Then, 
RdRp transcribes the successive genes, recognizing all of the cis-acting stop, 
polyadenylation, IG and start sequences, to produce a full set of viral mRNAs. Once a 
sufficient concentration of N is achieved, the signal(s) at the leader–N junction would 
be masked, perhaps by RNA encapsidation with the N protein, thus driving the switch 
in RdRp activity/function to its replicative mode to begin synthesis of an antigenome 
RNA. This antigenome is subsequently used as template for the production of new 
genomes. This theory is in agreement with the observation made by Wertz et al. 
(1998) in which, if the N protein transcription unit is moved further downstream into 
the genome, less N protein is produced and genome replication is reduced. However, 
increasing the amount of N protein produced in a minireplicon system for respiratory 
syncytial virus (RSV) does not enhance the rate of replication relative to transcription 
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(Fearns et al., 1997). More recent works have led to revision of the model since it is 
increasingly clear that the switch mechanism is more complicated. It is now thought 
that transcription and replication require different sets of accessory proteins to interact 
with the RdRp to form either a transcriptase or a replicase complex. Gupta et al. 
(2003) and Kolakofsky et al. (2004) proposed the existence of two different forms of 
the RdRp, one which is used for transcription and the other for replication. It has long 
been understood that both L–P and N–P complexes are essential for the replication 
process and that association of P with N maintains the latter in a soluble form ready to 
encapsidate newly synthesized viral RNA, but not cellular RNAs, as the N–P complex 
requires an encapsidation signal to bind the RNA (Horikami et al., 1992; Spehner et 
al., 1997). In the Gupta model, the transcriptase complex is formed by a RdRp 
associated with a L-P oligomer and possible host cell factors and differs from the 
replicase, which is formed from a tripartite association with the additional 
involvement of a N-P oligomer. In the Kolakofsky model, the transcriptase complex is 
proposed to consist RdRp with a L-P oligomer and a free P oligomer, which will bind 
directly to the genomic RNA while in the replicase complex the L-P oligomer is 
associated with an N-P oligomer. In both models the N protein plays a major role in 
determining the replicase activity. The M protein may also be involved in the 
regulation of RdRp activity and the inhibitory effect of M on VSV transcription has 
been known for many years (see review by Banerjee, 1987). This inhibition has also 
been shown to occur in MV and in rabies virus (RV) (Suryanarayana et al., 1994; 
Ghildyal et al., 2002; Finke S., and Conzelman K.K., 2003; Finke et al., 2003; Reuter 
et. al., 2006). The inhibitory effect of M seems to be independent of its role in virus 
assembly and budding, the amino acid residue at position 58 in the RV M protein 
being critical for this function (Finke and Conzelmann, 2003). The exact mechanism 
underlying M protein inhibition is not yet fully understood but, if the transcriptase 
complex is functionally different from the replicase complex, it might target the 
transcriptase directly and leave the replicase unaffected.  
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Geographic distribution 
PPR was first described in Côte d’Ivoire (Gargadennec L. & Lalanne A., 1942) 
and then afterm it has been recognized in many of the sub-saharian countries that lie 
between the Atlantic Ocean and the Red Sea (Lefevre and Diallo, 1990). The affected 
area extends north to Egypt and south to Kenya, in Eastern-Africa, and to Gabon, in 
Western-Africa. PPR has not been recognized in most of Northern and Southern-Africa. 
In 1998, serological survey in the United Republic of Tanzania did not detect any 
antibodies to PPR suggesting that infection has not extended that far to the south. PPR is 
present in nearly all Middle Eastern countries up to Turkey (Furley et al.. 1987; Lefevre 
et al. 1991; Perl et al. 1994; Taylor et al. 1990, Ozkul et al. 2002). It is also widespread 
in India and southwest Asia (Shaila et al. 1989). 
 PPRV strains classification has been achieved by sequencing the F and N genes 
(Shaila et al. 1996; Kwiatek et al., submitted for publication). Four geographic lineages 
were thus identified. Figure 3 represents the geographical distribution of the different 
genotypes of PPRV, according to the results of sequencing of the variable fragment of the 
N gene (3' extremity of the gene). There are four groups of phylogeny of which, 3 are 
located in Africa. The fourth group is the only one present into the Indian sub-continent but 
it also coexists in the Middle East with the East African group III (Figure 3). 
 
It is still not clear whether the apparent geographical spread of the disease in the 
last 50 years is real or reflects increased awareness, wider availability of diagnostic tools 
or even a change in the virulence of the virus. It seems most likely that a combination of 
factors is responsible for the present knowledge of the disease distribution. It is also 
known that confusion of PPR with pneumonic pasteurellosis and other pneumonic 
diseases of small ruminants has precluded and delayed its recognition in some countries. 
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Figure 3:  Geographic distribution of Peste des Petits Ruminants. I, II, III & IV 
correspond to different lineages of PPR distributed around the world. 
 
 
Economic incidence 
Although PPR remains the principal killing diseases of small ruminants in most 
African, Asian and Middle East countries as recognized in an international survey report 
published in 2002 (Perry et al., 2002), few economic studies have been made on this 
disease. The most recent one was published in 1992. It was conducted in Niger (Chip S., 
1992). It concluded to an anticipated minimum net present value (NPV) return of 14 
millions dollars with an investment of 10 millions dollars and internal rate of return (IRR 
> 100%) if the cost of the vaccination programme were to be increased five-fold. 
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Sanitary and Medical Prophylaxis 
There is no specific treatment against PPR. Antibiotics may prevent secondary 
pulmonary infections but this treatment is too costly in case of an outbreak. Therefore the 
control of this disease is through the implementation of sanitary and medical prophylaxis 
measures. 
Sanitary prophylaxis 
Although it is obvious that strict sanitary measures are hardly possible in developing 
countries where the disease exists, the following measures are recommended to be 
applied: 
- Isolation of infected herds and sick animals for at least 45 days after recovery 
- Slaughtering of infected herds (as far as possible) 
- Proper disposal of carcasses and products 
- Stringent disinfection  
- Quarantine before introduction into herds  
- Animal and vehicle movement controls within the infected areas 
Medical prophylaxis 
In the absence of homologous vaccine, and taking advantage of the close 
antigenic relationship between RPV and PPRV, the attenuated tissue culture Rinderpest 
vaccine has been used for a long time to protect small ruminants against PPR. At the end 
of the 80s, a PPRV strain was successfully attenuated by serial passages in Vero cells 
(Diallo et al., 1989). Demonstrated to be very efficient in the protection of sheep and 
goats against a virulent challenge, this avirulent PPRV is now widely used in the control 
of PPR.  
The fact that both of the above heterologous and homologous vaccines require 
effective cold chain to conduct a vaccination campaign, the costs required in poor 
African countries are enormous. To cut down the cost of vaccination, it would be 
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advisable to use not only a thermoresistant vaccine but also a polyvalent vaccine for the 
control of another important disease together with PPR. The thermostability of the 
current PPR homologous vaccine has been dramatically improved by a new freeze-drying 
process and addition of stabilizing agents (Worrwall et al., 2001). The objective of our 
work was to produce such another type of vaccine that would enable protection of sheep 
and goat against PPR and capripox, another serious disease of sheep and goats in PPR 
endemic areas. Therefore, to address the above problems, we have used the genetic 
recombination techniques by taking the cDNA corresponding to the genes of PPR 
proteins F and H responsible for protective immunity and inserting them in to the genome 
of capripoxvirus as a vector. Similar work has already been achieved in view of obtaining 
a recombinant vaccine against Rinderpest disease (Romero et al., 1993; Romero et al., 
1994a; Romero et al., 1994b). The next part of this document will give some information 
on poxviruses as etiologic agent of diseases in ruminants and as recombinant vectors for 
vaccination. 
 
SHEEP AND GOAT POX 
Definition 
Sheep and goat poxes are acute to subacute diseases of sheep and goats caused by sheep 
pox and goat pox viruses, respectively. They are characterized by generalized pox lesions 
throughout the skin and mucous membranes, a persistent fever, lymphadenitis, and often a focal 
viral pneumonia with lesions distributed uniformly throughout the lungs. Sub-clinical cases may 
occur. Capripoxvirus infections of sheep and goats result in major economic losses, and place 
constraints on both international trade and the introduction of exotic breeds to endemic areas 
(Davies F.G., 1981). They are part of the group of animal diseases to be notified to the World 
Organisation for Animal Health (OIE: Office International des Epizooties). 
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Symptoms 
Symptoms of sheep and goat pox are identical and therefore are not descripted separately. 
Usually, three forms of sheep and goat pox are described: per acute, acute and subclinical: 
a) The per acute form: is observed mainly on young animals and is characterized by the 
exacerbation of general signs of any acute infection, the hyperthermia and the depression. 
Sometimes the animal dies before the appearance of the skin lesions of the disease. In adults, this 
form is characterized by general eruption of hemorrhagic papules. 
 b) The acute form: is the most frequent and the most characteristic form of sheep pox and goat 
pox. It develops in 4 phases: incubation, invasion (the general symptoms phase), eruption then 
recovery. The incubation phase has a very variable duration, from 4 days to 3 weeks with an 
average of one week. The invasion or prodromal phase lasts 2 to 4 days and is characterized by 
general signs of acute infections: fever, depression, inappetence, trembling and accelerated 
breathing. During this period, different symptoms can appear such as that of rhinitis (sero-
mucosal discharge then muco-purulent) and conjunctivitis (photophobia and lacrimation). After 
this phase, follows the eruption during which the preceding symptoms become blurred. The 
eruptive phase can take two different forms: 
 
1. Classical pox. It starts with the appearance of circular hyperaemic spots (macula). This 
lesion progresses to a raised, slightly blanched lesion that presents erythema with edema 
in the central part of the lesion, the papule. Its preferential location sites are the perineum, 
inguinal area, scrotum, udder, muzzle, eyelids and axillae. It can also invade the neck, 
thorax, abdomen and the internal part of hind legs. Then the centre of the lesion becomes 
depressed and gray (necrotic). It is surrounded by an area of hyperemia. Late in the course 
of the disease (2 to 4 weeks after the first signs), the lesions become dry, and form scabs. 
Pox lesions with a transudate, representing the vesicular stage of the lesion, may be noted. 
These vesicles evolve into pustules. A characteristic feature of pox lesions is that they 
involve the entire epidermis and dermis and penetrate into the subcutaneous tissue; it 
looks like a nodule. Depending on the severity of the skin lesion, there may be a scar, an 
area devoid of wool or hair, after the lesion heals. Secondary bacterial infection may 
complicate the healing process. 
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2. Nodular pox or “STONE-pox”. In this form, papules give rise to firm circumscribed 
nodules with variable diameters that can be as large as 5 cm. They are named “stone pox”. 
They involve all the layers of the skin and the subcutaneous tissue and upon necrosis and 
sloughing they leave a hairless scar. They are specially localized on the head, neck, back, 
genital organs and udder. Sometimes, the nodules are scattered to the whole body. These 
will persist for several days and even several weeks then will sank themselves and form 
crusts. 
Some other clinical manifestations such as bronchial pneumonia and keratitis can be added to 
the above-mentioned symptoms following bacterial complication. Abortion due mainly to 
fever may also occur. 
c) Subclinical forms. They generally remain undetected and consist of transient pyrexia and 
inappetence, with some limited skin lesions. 
Some atypical forms of capripox characterized by meningitis signs, agitation and coma, or by 
gastroenteritis, have been reported. 
 
Aetiological agent 
The causal agents of sheep and goat pox are viruses which belong to the Capripoxvirus 
genus, along with the Lumpy skin Disease virus (LSDV), a pathogen of cattle and possibly 
buffalo. This genus is part of the subfamily Chordopoxvirinae within the family Poxviridae. All 
those three viruses cannot be distinguished serologically and thus they form one serotype. 
Differentiation can be made between them on the basis of their animal species pathogenicity: 
LSDV causes disease in cattle, sheep isolates are more pathogenic in sheep than in goat and the 
opposite is true for goat isolates. However they are some strains which cause serious disease in 
both sheep and goats (Davies F.G., 1976; 1981; Kitching and Taylor, 1985). The early electron 
microscopy observations of these viruses suggested that they could be distinguished according to 
their size (Tantawi and Falluji, 1979; Munz and Owen, 1966). However, Kitching and Smale 
(1986), analysing intact forms of different capripoxvirus isolates, did not find significant 
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differences in their external dimensions. Ovoid, all virions have an average seize of 294x273 nm. 
Not differentiable on the morphology basis or even by serology, capripoxviruses were thus 
classified according to their animal origin: sheeppox virus (SPV), goatpox virus (GPV) and 
lumpy skin disease (LSDV) isolated from sheep, goat and cattle respectively. Their genomes are 
double stranded DNA with terminal repeated sequences at each end (Gershon and Black, 1987). 
Early molecular studies of these genomes indicated the usefulness of restriction endonuclease 
analysis for the comparison study of capripoxvirus strains (Black et al., 1986; Kitching et al., 
1989). Indeed, although the patterns of capripoxvirus DNA generated by the digestion with Hind 
III are similar, confirming the close relationship between viruses within the genus, they have 
some specific differences that can be related to the animal origin with the exception of the Kenya 
sheep pox isolate KS1 which is in fact a LSD virus (Black et al., 1986). The comparison of these 
physical maps has also showed that genetic recombination between viruses within a single host 
might occur in nature (Black et al., 1986; Gershon et al., 1989). Such events might be rare. 
Indeed, although animal movements and consequently the frequency of contacts between 
different animals are important in Sub-Saharan Africa, Kitching et al. (1989) have shown by 
Hind III DNA digestion that cattle field isolates of capripoxvirus have been very stable over a 
period of 30 years. From the genome sequence, capripoxviruses seem to closely resemble 
leporipoxviruses within the family Poxviridae in term of gene content and organisation 
(Gesrshon and Black, 1989; Tulman et al., 2001). The full genome sequences for some strains of 
all three capripoxviruses are now available (Tulman et al., 2001; 2002; Kara et al., 2003). They 
are long of about 151 Kbp and contain 156 putative genes. The sequence data confirm the close 
relationship between capripox, sheeppox and lumpy skin diseases viruses: they share 96 to 97% 
nucleotide identity (Tulman et al., 2002). Comparison of these sequences with those of other 
mammalian poxviruses has shown a high degree of colinearity and amino acid identity in the 
central region of the genome. This similarity is disrupted in the terminal regions that contain 
genes potentially involved in viral virulence and host range. Indeed, the main differences between 
LSDV in one hand and sheeppox and capripoxvirus genomes in the other hand are located in the 
same areas: nine LSDV genes with likely virulence and host range functions are disrupted in the 
capripox/sheeppox virus genomes. It is also in the same regions where are identified gene 
changes between virulent and attenuated strains of the different capripoxviruses (Tulman et al., 
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2002; Kara et al., 2003). A thorough investigation of genes located in these terminal regions 
might help developing more effective capripox vaccine. 
  
Geographical distribution 
Capripox diseases are endemic in Africa, the Middle East, the Near East and Asia. If lumpy 
skin disease (LSD) has been reported in Egypt and Israel, it is mainly a disease of African 
countries south of the Sahara (Ali et al., 1990; Hafez et al., 1992; Greth et al., 1992; Yeruham et 
al., 1995). Sheeppox and goatpox are more widely spread than lumpy skin disease. Indeed, their 
endemic areas extend from China to Afghanistan, Turkey, the Middle East, and all African 
countries north of the Equator. In the 90’s, occasional sheeppox outbreaks were reported in 
Bulgaria and Greece. In Africa, three epidemiological situations of capripox infection are found: 
while in the region located between South of the Sahara and North of the Equator coexist the 
three viruses, Southern Africa and North Africa with the exception of Egypt, have only LSD or 
sheeppox, respectively (Diallo A. and Viljoen G., 2006).  
Sanitary and Medical Prophylaxis 
Sanitary measures 
Capripox diseases are infectious transboundary diseases and the most effective sanitary 
measure to prevent their introduction into non-infected areas is the control of animal movements.  
If a new case is confirmed in an area before extensive spread occurs, this area should be 
quarantined, infected and exposed animals should be slaughtered, and the premises cleaned and 
disinfected. Vaccination of susceptible animals on premises surrounding the infected flock(s) 
should be considered.  
If the disease has spread over a large area, the most effective means of controlling losses 
from SGP is vaccination. However, consideration should be given to the elimination of infected 
and exposed flocks by slaughter, properly disposing of dead animals and contaminated material 
and cleaning and disinfecting contaminated premises, equipment, and facilities.  
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Medical measures 
In endemic areas, vaccination is an effective means of controlling losses from SGP. 
Several modified live virus vaccines have been used for protection against SGP (Kitching, 1983; 
Kitching, 1986a; Kitching, 1986b; Carn, 1993; Bhanuprakash et al. 2004). For sheeppox, one of 
the vaccines which have been widely used is the sheeppox virus Rumania strain. It has been 
attenuated by serial passages in lamb kidney cell culture (Ramyar and Hessami, 1967; Ramyar 
1965 and Sabban, 1957). One of the goatpox live vaccines is the Mysore strain, which was 
attenuated on goat testis cells.  
Davies, (1976) described the isolation of the 0240 capripox virus strain from a sheep. It 
has been proved that this virus, also named KS1 for Kenya Sheep-1, is in fact a LSDV (Black et 
al., 1986; Tulman et al., 2002). Attenuation of this isolate, gave rise to a vaccine to control sheep 
and goatpox (Kitching et al., 1987). The immunity it provides lasts over one year and protects 
against generalized infection following for at least three years. This vaccine is recommended for 
the control of capripox in both sheep and goat but not in cattle because it seems to have residual 
pathogenicity for some breeds of this species (OIE Manual, 2004; Yeruham et al., 1995).   
Since 1984, many poxviruses are used as vector to express foreign genes for research purposes or 
for the development of recombinant vaccines. Because capripox viruses are host specific, the 
possibility to use their attenuated strains for that purpose was explored successfully in the 1990’s.  
 
Poxviruses as expression vectors 
Generalities 
Poxviruses have been extensively investigated as vaccine vectors because a) they activate 
both humoral and cellular immunity depending upon the promoter controlling the expression of 
the immunogen (Coupar et al., 1986; Andrew et al., 1989; Zavala et al., 2001 and Willey et al., 
2003), b) have the capacity to accommodate over 25 kb of extra DNA (Smith and Moss, 1983; 
Merchlinsky and Moss, 1992) and c) they allow simultaneous expression of several foreign genes 
(Perkus et al., 1985; Carroll et al., 1998; Welter et al., 2000). The possibility to use poxvirus 
virus as potential vector foreign gene expression was demonstrated for the first time in 1982 
simultaneously by Paoletti and Moss groups (Panicali D & Paoletti, E. 1982; Mackett et al. 
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1982). Two years later, this was followed by the development of the vaccinia-rabies recombinant 
vaccine which express the rabies virus surface glycoprotein (Kieny et al., 1984) and which has 
been used successfully in rabies control in wild life (Brochier et al., 1995; 1996). Since then 
numerous strains of vaccinia were engineered to express a variety of antigens from a myriad of 
bacterial, viral, and parasitic pathogens with subsequent evaluation of the recombinants in both 
animal models as well as target species. Vaccinia virus (VV) has been particularly used because 
of its well-defined molecular characteristics and its success in the WHO vaccine programme to 
eradicate smallpox (WHO, 1980; Moss B., 2001). This success was made possible because, 
among other features, the vaccine used in this disease eradication programme, the vaccinia virus, 
a) could be produced efficiently and at low cost in regional centers, b) its ability to retain potency 
as a freeze-dried preparation, c) its thermotolerance which facilitate a safe storage and transport 
to remote regions of the globe, d) the ease of its administration (different routes can be used 
efficiently). However, the use of this vaccine on a large scale led to undesirable effects like 
necrosis at the injection site, progressive vesicular eruption, encephalitis and sometimes death. To 
overcome these side-effects, the possibility of using highly attenuated vaccinia as vector for 
development of recombinant vaccines has been investigated. Such virus strains have been made 
available and were proved to be very efficient in induction of both humoral and cellular immunity 
against the recombinant protein. This is the case of modified vaccinia Ankara (MVA) which has 
lost about 15% of the VV genome containing host range and virulence factors genes. Its 
replication is defective in human cells (Blanchard et al., 1998).This is the case also for the 
NYVAC vaccine which derives from the Copenhagen VV strain after deletion of 18 genes from 
the viral genome and involved in the pathogenicity of the original virus (Tartaglia et al., 1992; 
Hel et al., 2002). 
Still because of vaccinia safety concerns, other investigations were made for use of host 
specific poxviruses such as avipox viruses. Their productive infection is restricted in vivo to avian 
species and in vitro to cells derived from avian species. However, inoculation of mammalian cells 
with avipox-based recombinants results in expression of foreign genes, and their inoculation to 
mammals results in the induction of protective immunity (Taylor and Paoletti, 1988; Taylor et 
al., 1988; Taylor et al., 1992; Cadoz et al.., 1992; Kent SJ, et al., 1994; Fries et al., 1996; 
Stannard et al., 1998; Vazquez-Blomquist et al., 2002; Nacsa J et. al., 2004).  
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Capripox virus as a vector 
 Capripoxviruses are also being targeted as vectors for foreign gene expression as they are 
highly host-range restricted and a number of attenuated strains have been used effectively as 
vaccines for many years (Kitching et al., 1987; Hunter and Wallace, 2001). The attenuated KS1 
strain was used as vector to express either the fusion or haemagglutinin genes of rinderpest virus 
and the resultant recombinant viruses were used successfully to protect cattle against both 
rinderpest and LSD (Romero et al., 1993; Romero et al., 1994a; Romero et al.., 1994b; Ngichabe 
et al., 1997). They were used also to cross protect sheep and goats against peste des petits 
ruminants (Romero et al., 1995). However, the KS-1 recombinant virus expressing the major 
core structural protein (VP7) of blue tongue virus (BTV) provided only partial protection to 
sheep against a virulent heterotypic BTV challenge (Wade-Evans et al., 1996). Like KS1, the 
LSDV vaccine Neethling strain has been used also as a vector to deliver antigens. A LSDV 
recombinant for rabies glycoprotein has proven to induce immune responses in cattle and in mice 
(Aspden et al., 2002; Aspden et al., 2003). Identically, a LSDV recombinant for G1 and G2 
glycoproteins of Rift Valley Fever induced protection in mice (Wallace et al., 2006).  
The capripoxvirus vector has two major advantages over vaccinia when it comes to 
veterinary vaccine applications. Firstly, it is not a human pathogen and the same safety problems 
do not arise. Secondly, it is already used as a veterinary vaccine to protect against sheeppox, 
goatpox and LSD infections (Kitching et al., 1987). Its use as a vector for expressing gene of 
foreign immune protective proteins offers the possibility to develop multivalent vaccines for 
ruminants and thereby the possibility to cut down the cost of vaccination campaigns. 
 
Conclusion 
Poxviruses as vehicles for gene expression and recombinant vaccines have come a long 
way in almost 20 years. This period has seen vast improvements in selection strategies, 
vaccination regimes and applications (Kwak et al., 2004). Now that the genome of many 
poxviruses has been sequenced, it has become possible to assign functionality to most poxvirus 
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genes. This has opened up new avenues for the design of improved vectors for use in 
vaccinology, immunotherapy and cancer therapy (Jackson et al., 2001; Boyle et al., 2004).  
In the vaccinology area, and with the view to develop tools that may help in the control of 
important small ruminant diseases, we have used capripox as host specific vector for expressing 
PPRV immunoprotective genes and tested the resultant recombinant viruses for their capacity to 
protect animals against two diseases following a single inoculation.  
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CHAPTER TWO 
 
Construction of recombinant vaccines  
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Introduction  
 
As indicated in the previous chapter, PPRV is an enveloped virus which contains two 
external glycoproteins, the fusion (F) and the attachment or heamagglutinin (H) proteins. These 
two proteins are needed and are essential in the initial step of the viral infection. This starts by the 
attachment of the virus to the target cell through the interaction between H and a cell surface 
protein used by the virus as the receptor. Following this attachment, F mediates the fusion of the 
viral envelope with the cell membrane to enable delivering the nucleocapsid into the cytoplasm 
where subsequent steps of the virus multiplication take place (Choppin P.W. and Scheid, A., 
1980). By virtue of their functions in the virus replication, the host protective immune responses 
are directed against (Merz et al., 1980; 1981). It is why we have genes corresponding to these 
two proteins for the development of recombinant capripox viruses as potential vaccines to protect 
small ruminants against both capripox and PPR infections.  
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FPPRV/Capripox recombinant construction 
 
 
 
The next article describes the strategy adopted to generate the recombinant capripox/ FPPRV 
and the results of in vitro and in vivo expression of the transgene. We have shown that the 
FPPRV recombinant capripoxvirus, at doses as low as 0.1 PFU, can protect goats against PPR 
disease despite the fact that an abortive multiplication of the challenge virus may had occurred.  
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HPPRV/Capripox recombinant construction 
 
This part of the work was published in a condensed form in the proceedings of New-York 
Academy of Sciences, reproduced here below. A complete manuscript was written thereafter and 
is included in the next pages. Submitted to the review Vaccine, this manuscript has been rejected. 
Although both reviewers have considered that the data were valid, one of them stated that the 
paper was too thin for publication in vaccine. Therefore, it is intended to submit this work to 
another review, possibly enriched with the results on the efficacy of different promoters which 
are detailed in the next section. 
 
Nevertheless, this work shows that the HPPRV recombinant capripoxvirus, with doses as 
low as 10 TCID50, can protect goats against PPR disease. All vaccinated goats survived while 
unvaccinated goats died. However, only two out of three goats vaccinated with the lower dose 
(0.1 TCID50) did not show any clinical sign after PPRV challenge while the third one showed an 
increase of its body temperature (Figure 3 in manuscript 3). On the other hand, all goats 
vaccinated with the two highest doses did not have detectable amount of PPRV RNA in their 
peripheral blood mononuclear cells (PBMC, see details in Table 1 of manuscript 3). Nonetheless, 
goats vaccinated with 10 or 0.1 TCID50, although clinically protected, have PPRV RNA in their 
PBMC, thus illustrating they were infected by the challenge virus. Since all animals vaccinated 
with the two highest doses of the recombinant had already serum antibodies two weeks post-
vaccination, we were not able to measure a boosting effect after PPRV challenge. However, this 
does not mean that the recombinant capripoxvirus did induce a sterilizing immunity, preventing 
the replication of PPRV. In fact, like for the FPPRV recombinant capripoxvirus, this recombinant 
probably needs improvement of its intrinsic immunogenic capabilities. This was attempted later 
on by trying to increase the level of antigen expression with different promoters (see next 
section). 
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SUMMARY 
The capripox virus KS1 was used as a vector to express the peste des petits ruminants 
virus (PPRV) haemagglutinin protein (H) under the control of a synthetic poxvirus 
promoter. The PPRV recombinant protein produced reacted strongly in an 
immunofluorescence test using a monoclonal antibody specific to PPRV H protein. 
Evaluation of the immune response of goats to this recombinant virus showed the 
production of PPRV neutralizing antibodies in animals that were inoculated with a dose 
of 10 TCID50 or more of the virus. All these goats resisted challenge with a virulent strain 
of the virus. The minimum protective dose was lower than that obtained with either a 
capripox or vaccinia-based rinderpest haemagglutinin recombinant vaccine but was 10-
fold higher than that for a recombinant capripox virus expressing the PPRV fusion 
protein (29).  
 
Keywords: recombinant vaccine; capripox vector; PPR, morbillivirus 
 
Short title: Capripox-based PPRV haemagglutinin recombinant vaccine 
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1. INTRODUCTION 
Peste des petits ruminants (PPR) is a highly contagious disease of small ruminants and is 
one of a group of animal diseases for which outbreaks must to be reported to the World 
Organisation for Animal Health (Office International des Epizooties: OIE). It is a disease 
which constitutes the main constraint to the increased production of sheep and goats in 
many African countries south of the Sahara, in the Middle East, in Turkey and in South 
Asia (1; 2; 3). Thus its control is a major concern for poverty alleviation in many parts of 
Africa and South Asia (4). A live-attenuated vaccine derived from the PPRV Nigeria 
75/1 strain by serial passage on Vero cells is currently used to control this disease in 
some areas (5). For use in countries with hot climates, its thermostability has been 
improved by dehydration of the virus suspension in the presence of trehalose (6). A 
recent investigation revealed that, even though many countries consider PPR to be an 
economically important disease, most implement vaccination campaigns only when 
outbreaks are detected and with the objective of limiting the spread of disease (7). One 
of the factors which may explain why so few countries undertake systematic vaccination 
campaigns to control PPR is certainly the high cost of the logistics needed to vaccinate 
small ruminants whose populations are scattered widely over large areas. A way to 
increase the cost effectiveness of vaccination is to attempt to control more than one 
economically significant disease of sheep and goats in the same operation using 
multivalent vaccines. Capripox virus appears to be an ideal vector for the development 
of such vaccines for ruminants (8). The causal agent of peste des petits ruminants is a 
virus, the Peste des petits ruminants virus (PPRV), which is classified in the 
Morbillivirus genus within the family Paramyxoviridae (9). This genus includes other 
closely related animal and human pathogens: rinderpest virus (many species of 
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ruminants), measles virus (humans), canine distemper virus (carnivores), phocid 
distemper virus (seals) and the cetacean morbilliviruses (whales, dolphins and 
porpoises). As is the case for other paramyxoviruses, PPRV is an enveloped non-
segmented negative sense single-stranded RNA virus with two external glycoproteins, 
the fusion (F) and haemagglutinin (H) proteins. These proteins are indispensable for 
infection of host cells by the virus and following attachment and fusion of the virus 
envelope with the host cell the viral nucleocapsid is delivered into the cytoplasm where 
virus replication takes place. The H protein mediates attachment of the virus to the host 
cell membrane via its interaction with the cellular receptor(s) while the F protein enables 
the virus to penetrate into the cell by effecting fusion of its membrane with that of its 
target cell. With some paramyxoviruses, including PPRV, the F protein alone cannot 
effect cell fusion and it needs the cooperation of the H protein (10; 11; 12; 13; 14). 
Moreover, in the case of PPRV and rinderpest virus (RPV), two closely related ruminant 
viruses, it has been demonstrated that the H protein gene of one virus cannot be replaced 
by that of the other to allow effective activity of the F protein and virus viability (15), 
therefore these two proteins are absolutely required for the initiation and propagation of 
the viral infection. They are also the two viral proteins which have been shown to 
provide protective immunity against morbillivirus infections (16; 17; 18; 19; 20) and 
both F and H have been used to develop effective recombinant morbilliviruses vaccines 
(21; 22; 23; 24; 25; 26; 27; 28). Most neutralizing antibodies produced in an infected 
animal are directed against the H protein, the protective property of the F protein being 
mostly through cell-mediated immunity (18). In a previous publication, we reported on 
the insertion of the PPRV F gene into the capripox virus genome and on the efficacy of 
this recombinant virus as a dual vaccine to protect small ruminants against both capripox 
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and PPR infections (29). Here we report on the construction of a recombinant capripox 
virus expressing the PPRV H protein and the results of a preliminary trial in goats as a 
vaccine against PPR.  
 
2-MATERIALS AND METHODS 
2-1. Cells and viruses. 
Primary lamb testis (LT) and Vero cells were used to propagate capripoxviruses and 
PPRV respectively. LT cells were grown in Dubelco’s modified Eagle’s medium 
(DMEM) supplemented with 10% foetal calf serum (FCS) and antibiotics. For Vero 
cells, the growth medium used was Eagle’s minimal essential medium (MEM) 
containing 10% FCS and antibiotics. The attenuated capripoxvirus Kenya sheep-1 (KS-
1) vaccine was used as the vector virus (30). The virulent PPRV Guinée Bissau /89, a 
virus strain isolated from a goat during a PPR outbreak in Guinée Bissau in 1989 (Diallo 
A., unpublished data), was used as the challenge virus in the vaccine trial (29).  
 
2-2 Construction of the recombinant 
The transfer vector, pKSCATPSG (figure 1), was constructed in our laboratory. It is a 
pBluescript II KS plasmid into which was inserted a back-to-back poxvirus synthetic 
double early/late promoter (see sequence in figure 1a). This double synthetic promoter 
(PS), a gift from Dr R. Drillien (Strasbourg, France), was proved to give strong protein 
expression in the vaccinia virus vector system (31). To enable homologous 
recombination between the transfer vector and the capripox viral genome, a fragment of 
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the capripox virus thymidine kinase gene (TK) was inserted at each end of the plasmid 
polylinker. They were 288 and 396 base pairs (bp) long and are indicated in figure 1b by 
TKL for TK left, and TKR for TK right, respectively. The plasmid also contains the E. 
coli xanthine-guanine-phosphoribosyltransferase gene (Eco gpt) under the control of one 
of the synthetic promoters. Eco gpt was used as the dominant selectable marker to isolate 
the recombinants (32; 33). A number of unique restriction enzyme sites used for the 
cloning of foreign inserts are located downstream of the second promoter. As indicated 
in figure 1, cDNA corresponding to the haemagglutinin gene of the PPRV vaccine strain 
Nigeria 75/1 (accession number Z81358 or X74443) was inserted into pKSCATPSG 
between the Sma1 and Not1 restriction sites. The final construct, plasmid pKSCATP-H, 
was used to generate the recombinant virus with the capripox virus KS-1 in LT cells as 
described previously (29). The virus obtained following transfection of capripoxvirus 
KS1-infected cells with the transfer plasmid pKSCATP-H was used to select the 
recombinants.  
 
2-3. Selection and characterization of the recombinants clones 
The method described by Romero et al. (26) and modified by Berhe et al., (29) was used 
to select the recombinants. Briefly, this was done by limiting dilution and plaque 
selection in the presence of selection medium which contains mycophenolic acid (MPA), 
xanthine and hypoxanthine. Before each dilution, the viral suspension was sonicated for 
30 sec in a water bath sonicator. The presence of the recombinant in viral suspensions 
and its purity were checked by PCR with both capripox virus TK and PPRV H gene-
specific primers. The capripox primers were designed in the TK gene of the capripox 
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virus KS-1: CPTK7 ACTTATCAGATTTTGTTACGACATT and CPTK8 
CGATGAGTTCTATTTCCTTTTCTTTAG. They bind to the transfer vector in the TKL 
and TKR fragments respectively. HP46 CGCACAAAGGGAAAGGATCA and HP47 
CTGATGCCGACTTCATCACC were the primers used to amplify a fragment of the 
PPRV H gene. The conditions of the PCR were those reported previously (29).  
 
2-4 Detection of the recombinant H protein 
The expression of the PPRV H protein by the recombinant capripox-PPRVH virus 
(recCapPPR/H) selected in the LT cells was confirmed by immunofluorescence as 
described previously (29). The PPRV H protein-specific monoclonal antibody used was 
the Mab B2G3 which was described previously (34). 
 
2-5. Vaccination and Challenge of goats 
Fourteen British goats of mixed breed were purchased and housed in 6 different groups 
in the high-security animal accommodation at the Institute for Animal Health, Pirbright 
Laboratory. Groups I, II, III, and IV were each composed of 3 animals that were 
inoculated by subcutaneous injection with 105, 103, 10, and 10-1 TCID50, respectively, of 
the recombinant virus recCapPPR/H. Group V, composed of 2 animals, did not receive 
any injection. The animals were examined daily for clinical signs of infection. One 
month later all animals, including the controls of group V, were challenged with the 
virulent PPR virus Guinée Bissau/89 strain at 104 TCID50/animal by subcutaneous 
injection. They were observed daily for clinical signs of PPR infection for two weeks 
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following challenge. Animals were bled every week for the collection of serum and 
every 2 days for the preparation of peripheral blood leucocytes (PBL) which were 
purified on Ficoll-Paque gradients according to the manufacturer’s instructions 
(Amersham Biosciences).    
2-6. Antibody Assay 
The sera were tested for the presence of antibodies against PPR using both the H-based 
cELISA as described by Anderson et al. (35) and the virus neutralisation test (VNT). The 
latter was performed in the 96-microwell plates. Briefly, 100 TCID50 of PPRV vaccine 
strain Nigeria 75/1 (5) in 100µl of cell culture medium were mixed with 100µl of the 
diluted test serum in the well.  Twofold serial dilutions were made from a 1/5 pre-
dilution and before use in VNT, the sera were heat-inactivated at 56 °C for 30 min.  
After 1 hour of incubation at 37°C, Vero cells (2 X 104) in 50 µl of cell culture medium 
were added. The plates were incubated at 37 °C and read at 10, 12 and 14 days for the 
detection of virus cytopathic effect (cpe). The 14 day reading was used to determine the 
titre. A serum was considered positive for PPRV neutralizing antibodies if no cytopathic 
effect was detected at dilutions of 1/10 or higher. 
 
2-7. Detection of the PPR challenge virus 
Total RNAs were extracted from PBL that were collected from the animals at various 
times after challenge. The extractions were made using RNeasy kit according to the 
manufacturer’s instructions (Qiagen). The RNAs were then submitted to RT-PCR tests 
as described previously to detect the N gene-specific RNA of the challenge virus (29; 
36).  
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3. RESULTS  
3-1. Isolation of the recombinant  
The methodology that proved to be quick and efficient for the selection of pure capripox-
based recombinant viruses, as outlined in Materials and Methods, that is limiting dilution 
of sonicated virus suspensions and verification of virus purity by PCR was followed (29). 
For this we used primers HP46 and HP 47 to amplify a fragment of 312 nucleotides on 
the PPRV H gene. The same sample was tested using another pair of primers specific to 
the capripox virus TK gene: primers CPTK7 and CPTK8 binding to TKL and TKR, 
respectively. In the absence of a foreign gene insert in the TK gene they allowed the 
amplification of a fragment of about 600 nucleotides from capripox genome. When 
recombination occurred the genome of the virus would contain both the PPRV H and the 
selection marker genes and the expected size of the amplified target would then be about 
2500 nucleotides. The conditions of elongation in the PCR reactions did not allow the 
amplification of targets greater than about 1000 nucleotides (29), thus if a virus 
suspension contained only the pure recombinant no DNA was amplified with primers 
CPTK7 and CPTK8, while the PCR would be positive with the HP46 and HP47 primer 
set. In the case of there being a mixture of recombinant and parental viruses, both sets of 
primers would give positive PCR products. After two limiting dilution selections using 
this technique, the recombinant viral suspension was plaque purified under low melting 
point agarose using. Five clones positive by PCR with the HP46-HP47 primers but 
negative with the CPTK7-CPTK8 primers were selected. One clone, recCapPPR/H, was 
used as a pure recombinant capripox virus-HPPR and stocks prepared for subsequent use. 
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The expression of the recombinant protein by this virus was confirmed by 
immunofluorescence using a PPRV H-specific monoclonal antibody (B23G) according to 
the method of Berhe et al., (29). As can be seen in figure 2, fluorescence was detected in 
cells infected with the recombinant virus but not in uninfected cells.  
 
3-2. Evaluation of the protective capacity of the recombinant recCapPPR/H virus in 
goats.  
To assess the ability of the recombinant recCapPPR/H virus to protect animals against 
PPR infection, twelve goats housed in groups of three were vaccinated subcutaneously 
with virus doses ranging from 105 to 10-1 TCID50/animal as indicated in Materials and 
Methods. Two goats to be used as challenge controls did not receive any injection of the 
recombinant. During the one month of clinical observation following vaccination, all 
animals remained healthy. After this period, the vaccinated animals and the two controls 
which did not receive any treatment were challenged with 104 TCID50 of PPRV Guinée 
Bissau 89/1. All goats in groups I, II, III and two of group IV (goats UD38 and 39) 
showed no clinical signs of PPRV infection. Their rectal temperatures remained normal 
during the two weeks of observation although animals UD 36 and UD 37, which were 
inoculated with 10 TCID50 of the recombinant virus, had rectal temperatures of 39.7 to 
39.9 °C for one or two days (figure 3). One goat, UF3, which received 10-1 TCID50 of the 
recombinant virus developed fever and leucopoenia (see below) for about one week but 
recovered. The two challenged control animals had high temperatures and other PPR 
clinical signs which were so severe that they were humanely euthanized at 11 and 12 days 
post infection. PPRV is a lymphotropic virus, as are all morbilliviruses, and leucopoenia 
is one of the clinical features of the disease. This parameter was evaluated in the present 
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study. At 0, 2, 4, 7, 9, 10 and 11 days post challenge, PBL were collected from all 
animals. The cells were counted and any reduction ≥50% in the number in comparison to 
that of the day of challenge was considered as a sign of significant leucopoenia. Based on 
that criterion, no abnormality was observed with animals vaccinated with 105-103 TCID50 
of the recombinant virus. All other animals develop leucopoenia lasting for at least one 
day following the challenge (data not shown). Growth of the PPRV challenge virus in the 
vaccinated animals was monitored by the detection of virus-specific RNA sequences by a 
PPRV N gene-based RT-PCR on total RNA extracted from the PBL. As can been seen in 
table 1, the test was negative with the PPRV specific primers NP3-NP4 for the samples 
collected from challenged animals of group I and II and also with one goat of the group 
III, UD 36. For the two other animals in group III, the RT-PCR was positive as for the 
control challenged goats. This indicated that 10 TCID50 of the recombinant recCapPPR/H 
is not sufficient to prevent replication of the challenge virus to a level detectable by RT-
PCR, even in absence of an overt disease.   
 
3-3. Serological response 
The results of assays to measure the serological responses in animals after vaccination 
with the recombinant virus but before challenge are summarised in table 2. Two different 
techniques, the VNT and the H protein-based competitive ELISA (cELISA), were used 
for the detection of PPRV antibodies. The positive / negative cut-off value in the cELISA 
was taken as 50% inhibition of the binding of the monoclonal antibody while for the 
VNT a serum was considered to have antibodies against PPRV if it neutralised the virus 
at a dilution of at least 1/10. Both tests were positive one to two weeks after vaccination 
for the goats inoculated with the recombinant virus at doses ranging from 105 to 10 
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TCID50. However, one animal of the group that received a vaccine dose of 10 TCID50, 
goat UD 37, showed a very weak antibody response only detected by cELISA in serum 
collected at 2 weeks post vaccination. All these animals were protected from PPR disease 
following virulent challenge. Within the group that received a dose of 10-1 TCID50, one 
animal, UD 38, showed a very weak positive PPRV antibody response, again only 
detected by cELISA. Serological tests remained negative for the two other goats. In the 
same group, only goat UF3 developed a pyrexic response which lasted for about one 
week following challenge.  
 
3. DISCUSSION  
In a previous study, we demonstrated the potential of a recombinant capripox virus 
expressing the PPRV F protein as an effective dual vaccine to protect goats against both 
capripox and PPRV infections. Here we report on the protective properties of another 
capripox-based PPRV recombinant vaccine. This new recombinant carries the second 
PPRV glycoprotein gene, that encoding the H protein. Three plasmids were used to 
construct the transfer vector containing the cDNA corresponding to the F gene (29) but 
the construction of the new transfer vector carrying the PPRV H cDNA was much 
simplified by the use of a plasmid containing a double poxvirus promoter, the selection 
marker gene and sequences of the capripox TK gene to enable homologous 
recombination to take place. The recombinant virus proved effective in protecting goats 
against PPR disease at a minimal dose of 10 TCID50. With the 10-1 TCID50 virus dose no 
animal died following virulent challenge but one animal got a high fever which lasted for 
about one week. Ten TCID50 of virus which was found to protect animal against overt 
disease on challenge is a dose far lower than that reported for poxvirus-based rinderpest 
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H recombinants. With the recombinant vaccinia-RPV H, a minimum dose of 104 – 105 
PFU is required to achieve complete protection of cattle against rinderpest (37) while 
with the capripox-based RPV H recombinant, 2.4x103 PFU were efficacious in protecting 
cattle against virulent rinderpest challenge (27). The disparity between these reports and 
the results from the present study may be explained by the differences in species and their 
response to the vector virus or by differences in the promoters that were used: promoter 
p7.5 for the vaccinia-RPV H, promoter p11 for the capripox-RPV H recombinant and a 
synthetic early/late promoter for the capripox-PPRV H. Another possible reason could be 
the degree of purity of the recombinants used. The purity of the rinderpest recombinants 
was not checked by the very sensitive PCR test, as was the case in the current study and 
the presence of some parental vector virus in the recombinant vaccine cannot be ruled 
out. If 10 TCID50 of recCapPPR/H virus is the minimal protective dose of goats against 
PPRV infection, this would represent a higher dose than the 0.1 PFU necessary for the 
capripox PPRV F recombinant (29). Both PPRV recombinants were selected using the 
same technique and the stocks were shown to be free of parental virus. The difference 
between these two capripox-based PPR recombinant vaccines may reflect either a better 
immunoprotective quality of the fusion protein compared to that of the haemagglutinin or 
a difference in promoter efficiency. While expression of the fusion protein is driven by 
the vaccinia virus promoter p7.5, expression of the H protein gene was placed under the 
control of a synthetic early/late promoter capripox. Work to compare the efficacy of 
different poxvirus promoters for the induction of protective immunity in goats against 
PPR disease is in progress.  
The results obtained with the capripox-based PPRV F and H recombinants are similar to 
those that have been reported for rinderpest recombinant vaccines and are consistent to 
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the observation that most of morbillivirus neutralising antibodies are directed against the 
haemagglutinin (18; 26; 27). However, there are indications that a humoral response 
alone is not the only basis of the protective properties of the haemagglutinin and that this 
protein may also induce a cell-mediated immune response (38; 39). This possibility may 
explain why goat UD 39, which did not show any detectable antibody response to the 
capripox-PPRV H recombinant at the dose of 0.1 TCID50, did not show a clinical 
response to the challenge virus although it replicated for many days in the animal as 
evidenced by the detection of virus-specific RNA in the PBL. Two T cell epitopes have 
been mapped on the PPRV H protein (39) and a baculovirus-expressed rinderpest H 
protein is only protective if delivered in a suitable T-cell inducing adjuvant such as an 
ISCOM (38).  A similar report on the protection of seals from phocine distemper virus 
(PDV) showed that inactivated canine distemper virus incorporated into ISCOMs was 
able to protect seals from the phocine distemper virus (40). Therefore the best way to 
deliver a PPRV single gene-based vaccine is through a system which can trigger both 
humoral and cellular immune responses, as happens with a live virus vector. For this 
purpose the capripox vector has the advantage of being very specific to cattle, sheep and 
goats without the adverse effect of vaccinia virus on the human population. Moreover, the 
capripox-based PPRV recombinant vaccine can be used to protect sheep and goat against 
both capripox and PPRV, two diseases which have a highly negative impact on small 
ruminant production in many developing countries (29).  
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FIGURE LEGENDS 
Figure 1. (a) Sequence of the synthetic early/late double promoter (31). Nucleotides in 
italic are elements required for the sequence to act as early or late promoter. (b) Strategy 
for construction of the transfer vector. Plasmid pKSCATPSG was derived from 
pBluescript into which a back-to-back double poxvirus synthetic early/late promoter, the 
Eco gpt gene and two fragments of the capripox TK gene, were inserted. The cDNA 
corresponding to the coding sequence of PPR H gene was amplified with the 
proofreading enzyme Pfu from plasmid pH78-2 using two primers, the HP78 
(ACCATGTCCGCACAAAGGGAAAGG) which starts at the ATG of the H gene ORF 
and the Bac Hist (ACAACGCACAGAATCTAGCG) binding to the original plasmid 
outside the H gene. The amplified product which is blunt at both ends was digested with 
Not 1 and ligated into the plasmid double digested with the restriction enzymes Not1 and 
Sma1. The sequence of the insert was checked before further use.  
 
Figure 2. Detection of the PPRV H protein by immunofluorescence staining. LT cells 
were infected with recCapPPR/H virus (a) or capripox virus KS1 (b). At two days post-
infection, they were stained for indirect immunofluorescence with a PPRV-specific anti-
H monoclonal antibody as previously described (29).  
 
Figure 3. Daily rectal temperatures of vaccinated and control goats after challenge with 
the virulent PPR Guinée Bissau/ 89 strain. The different doses of the recombinant 
recCapPPR/H virus used are indicated in each panel and the days post challenge on the 
X-axis. 
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Table 1: Detection of PPRV N gene-specific RNA in PBL collected from goats after challenge with the virulent PPRV Guinée 
The PCR test was performed as described by Berhe et al (29) and Couacy et al. (34). The β actin-specific primers
 were used to amplify the β actin mRNA as a control for the quality of the extracted RNA
Dose of virus
n° of goat UD32 UD33 UD41 UD34 UD35 UF1 UD36 UD37 UF2 UD38 UD39 UF3 UD40 UF5
Primers day post challenge
βActin + + + + + + + + + + + + + +
NP3/Np4 - - - - - - - - - - - - - -
βActin + + + + + + + + + + + + + +
NP3/Np4 - - - - - - - - - - - - - -
βActin + + + + + + + + + + + + + +
NP3/Np4 - - - - - - - + + + + + + +
βActin + + + + + + + + nd + + + + +
NP3/Np4 - - - - - - - + nd + + + - +
βActin + + + + + - + + + + + + + +
NP3/Np4 - - - - - - - + - - + + + +
βActin + + + + + + + + + + + + dead dead
NP3/Np4 - - - - - - - - - - + -
nd: not done  
105 pfu 103 pfu 10 pfu 0.1 pfu control challenge
D 9
D 11
D 0
D 2
D4
D 7
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Table 2: Results of  the serological tests to detect PPR antibodies in sera collected during the recombinant vaccine trial 
Dose of virus
n° of goat UD32 UD33 UD41 UD34 UD35 UF1 UD36 UD37 UF2 UD38 UD39 UF3 UD40 UF5
type of test week post vaccination
cELISA - - - - - - - - - - - - - -
VNT - - - - - - - - - - - - - -
cELISA - - - + + - - - - - - - - -
VNT - - - + - - - - - - - - - -
cELISA + + + + + + + + + + - - - -
VNT + + + + + + + - + - - - - -
cELISA + + + + + + + - + + - - - -
VNT + + + + + + + - + - - - - -W 3
control 
W 0
W 1
W 2
105 pfu 103 pfu 10 pfu 0.1 pfu
 
  89 
 
Figure 1a 
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Figure 3 
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Figure 3 
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Figure 3 
Group V: Control (unvaccinated animals)
37
37.5
38
38.5
39
39.5
40
40.5
41
41.5
42
0 1 2 3 4 5 6 7 8 9 10
Re
ct
al
 
te
m
pe
ra
tu
re
 
°C
UD40 UF5
 
 
  94 
Conclusion: 
 
 
 After vaccination with the first recombinant construction, the FPPR/capripox 
recombinant, no antibody anti F was detected in the serum of the vaccinated animals by the 
diagnostic test we have used. An anamnestic PPRV serological response was detected upon 
challenge. This result, in addition to the fact that the RNA of the challenge virus was detected in 
the white blood cells of some vaccinated animal, it also indicates that the tested recombinant 
virus is not providing sterile immunisation. This was the case with the recombinant capripox/H 
PPR using the synthetic promoter PS. As a consequence, the animals may excrete the virus so 
that it can propagate in the environment. 
 
 In order to increase the immunogenicity of the recombinant capripoxviruses to protect 
the vaccinees against the infection, we decided to work on the promoter efficacy. Promoters are 
short nucleic acid sequences that trigger the expression of genes. In our case, the capripox/F 
PPR construction was under the control of the classical vaccinia early/late p7.5 promoter while 
for the capripox/H PPR the early/late synthetic promoter was used as it was demonstrated to be 
a strong promoter (Chakrabarti et al., 1997). In that case the minimum protective dose of the 
recombinant, although expressed in different units, was much higher than the result obtained 
with the first recombinant: 10 TCID50 versus 0.1 PFU. The discrepancy of those results may be 
due to the quality of the protein, F being more effective than H in the protection induced by 
capripoxvirus, or due to the quality of the promoter. We therefore decided to test the efficiency 
of those two vaccinia-derived promoters along with a third one which was proved to drive 
synthesis of large amount of recombinant protein in the vaccinia system (Jin et al., 1994).  
 
In the next section, we describe results of the in vitro and in vivo comparison under the 
same conditions of three recombinant capripoxviruses containing the HPPRV gene under three 
different promoters. 
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CHAPTER THREE 
 
Comparison of promoter efficacy 
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Introduction 
 
Poxviruses are unique among DNA viruses since they complete all their replication cycle 
in the cell cytoplasm. Therefore the virus must bring into the cell or synthesize most of the 
proteins necessary for its gene expression, replication and virion assembly. Basically, the 
replication of poxviruses follows three phases (for review see Broyles S., 2003; Schramm and 
Locker, 2005). The phase one consists of the expression of early genes that help to uncoat the 
core and to mediate viral DNA release. The phase two consists of the replication of the viral 
DNA and expression of intermediate genes by transcription complexes synthesised during the 
early phase. The phase three concerns the expression of late genes by transcription factors 
expressed from the intermediate genes. The late genes produce the structural proteins of the 
virion. The virus coordinates its genome replication with the virion formation through the 
regulation of gene transcription by sequential activation of early, intermediate, early/late and 
late promoters. Activation sequences onto which attaches the RNA polymerase, the promoters, 
constitutes a key role in the control of downstream genes. Coupar et al. (1986) pointed out the 
importance of early expression of antigens by vaccinia virus for efficient priming of cytotoxic T 
lymphocytes (CTL) and thereby induction of long term immune response. Many foreign genes 
have been inserted under the control of the VV P7.5K early/late promoter either in the vaccinia 
virus or other poxviruses. Proteins under control of this promoter are known to stimulate both 
humoral and cell-mediated immune responses (Coupar et al., 1986; Andrew et al., 1989). Late 
promoters such as p11 (now referred to as gene F17) for vaccinia or the promoter for the gene of 
the A-Type inclusion body /ATI/ of cowpox virus direct high level protein expression (Ichihashi 
and Dales, 1973; Shida et al., 1977). However they do not stimulate strong cell-mediated 
immune response.  
The use of a promoter which will ensure high level of recombinant protein expression by 
a poxvirus at all stages of the infection will probably improve the induced immune response. 
With this in mind, we have compared the capabilities of three early/late promoters to direct the 
PPRV haemagglutin protein by the capripox virus vector: the VV p7.5, a synthetic promoter 
(PS) and a hybrid A–type inclusion body promoter/synthetic early promoter p7.5 (pATI16p7.5) 
(Chakrabarti et al., 1997; Jin et al., 1994)  
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Materials and Methods 
Recombinant vaccines 
Construction of the recombinant capripox/HPPR with the synthetic promoter (PS) is 
reported in chapter II. Here we report on the construction of the two other capripox/HPPR 
recombinant viruses in which the PPRV H protein gene is under the control of either the hybrid 
promoter pATI16p7.5 or the vaccinia promoter p7.5. The transfer vector plasmid pKSCATP-H 
was used to construct the recombinant capripox/HPPR with the synthetic promoter PS (see 
figure 1a and 1b of manuscript 3). In this plasmid, both PPRV H and the selection marker GPT 
genes are under the control of PS, a double early/late synthetic promoter. This plasmid was used 
in the construction of the two other capripox/HPPR recombinants in which the promoter element 
controlling the PPRV H gene is replaced by either the hybrid promoter pATI16p7.5 or the 
vaccinia promoter p7.5. It has been digested by PstI (Biolabs), then repaired with T4 DNA 
Polymerase (Biolabs) and digested again by HindIII (Biolabs). This double digestion eliminates 
the fragment of the promoter contolling H PPR gene (see figure 1a and 1b of manuscript 3). The 
plasmid pBSFJ2-16 (gift from Dr H. Shida, Kyoto University, Japan) contains the hybrid 
promoter pATI16p7.5. It was mutated to insert a HindIII restriction site upstream the pATI 
sequence. The new plasmid, pBSF2-16∆, was digested by EcoRI, repaired with T4 DNA 
polymerase and digested by HindIII to release the hybrid promoter fragment. It was gel purified 
along with the double digested plasmid pKSCATP-H using the Qiaquick gel extraction kit 
(Qiagen). Vector and insert were ligated with the DNA ligation kit (Amersham). DH5a E.coli 
strain was transformed with the ligation product. Colonies were directly screened by PCR with 
HP47 and Ati176 primers to produce a fragment of about 1500 bp. Positive clones were grown 
overnight at 37°C, 250 rpm on LB medium containing 1% ampicilline DNA was extracted from 
culture with Wizard Plus SV Minipreps DNA purification system (Promega). Then the clone 
was sequenced on ABI Prism 377 to confirm the construction. A large amount of the plasmid 
DNA was produced and extracted with Endofree maxi prep (Qiagen). The new plasmid is 
named pCA216-H. Another transfer vector plasmid was constructed by ligating into the 
HindIII/ECoRI doubled digested pKSCATP-H the promoter p7.5 that was released from the 
plasmid JC-35 (see in article 1). The resultant plasmid obtained was named pHPPRp7.5. Using 
the method described in Article 1 and manuscript 3, both pCA216-H and pHPPRp7.5 were used 
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to generate new capripox/H-PPR recombinant viruses which express the PPRV H protein under 
the control of the hybrid promoter pATI16-P7.5 or p7.5. 
 In vitro evaluation of H expression by the different recombinant 
capripox/HPPR viruses 
Culture cell flasks of 75 cm², containing OA3Ts cell monolayer at 80% of confluence were 
inoculated with each of the recombinant capripox/HPPR virus at 104.5 TCID50. The parental 
capripox virus KS1 was used as the negative control of the experiment. After 5 days of 
incubation at +37°C and 5% CO2, the cells were trypsinised and washed in PBS-5% horse 
serum-0.005% sodium azide-0.1% saponine (incubation buffer). The cells were then incubated 
for 30 minutes at +4°C in presence of one of the following antibodies appropriately diluted in 
the incubation buffer: 
- mouse monoclonal antibody anti-HPPR (IAH, Pirbright) at 1/100 
- sheep anti-pox serum (CIRAD) at 1/200 
- mouse negative serum at 1/400 
- sheep negative serum at 1/200 
 
The stained cells were then washed twice with the incubation buffer. They were incubated 
again for 30 minutes at +4°C with conjugate either anti-sheep FITC (ref F0135, Dako) diluted at 
1/40 or anti-mouse TC (ref M32006, Caltag) diluted at 1/100 in the incubation buffer. After two 
washes in the same buffer, the cells were finally re-suspended in FACs flow buffer and analysed 
in a FACsorter (Becton Dickinson). 
 
Evaluation of the different capripox/HPPR recombinant viruses 
for protection of Goats against PPR 
 Eighty (80) goats of both sexes, aged between 8-16 months, were purchased from the 
high land part of Ethiopia, expected to be “free” of PPRV infection. They were brought to the 
National Veterinary Institute of Ethiopia (NVI) in Debre Zeit. They were bled for serum 
collection. All samples were analysed at CIRAD-EMVT in Montpellier and NVI for the 
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detection of antibodies to the hemagglutinin protein of PPRV and RPV using specific PPRV and 
RPV monoclonal antibody-based competitive enzyme-linked immunosorbent assays (cELISA) 
developed by Anderson et al. (1991). The animals were treated by broad-spectrum 
anthelmentics (5.00 mg Albendazole per kg bodyweight). Following the screening test, those sera 
which were free from PPR or RPV antibodies were selected, tagged and randomly allocated to 
five different groups. They were immunised with different vaccines at doses varying from 0.1 to 
103 TCID50/animal by subcutaneous route (see table 1). The capripox/F PPR recombinant and 
the classical attenuated PPR vaccine were included as positive control in the experiment. 
Housing of animals was a well-ventilated and rodent proof. Three weeks after vaccination, 
animals were challenged with the virulent PPRV India 94/1 Vero 3. They were submitted to 
daily clinical observation. They were bled at day zero, 15, 30 and 45, last day of the clinic 
observation.  
 
 
     group 
 
dose 
Rec-H-p7.5 
(G1) 
Rec-H-PS 
(G2) 
Rec-H- 
pATI16p7.5 
(G3) 
Capripox-
FPPR 
(G4) 
Classical 
attenuated 
PPR 
vaccine. 
(G5) 
103 3 3 3 0 3 
102 3 3 3 0 0 
10 3 3 3 0 0 
1 3 3 3 0 0 
0.1 3 3 3 3 0 
0 (negative 
controls) 
2 2 2 2 2 
Total 17 17 17 5 5 
 
Table 1: Experimental design for the comparison of promoters  
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Result and discussion 
In vitro quantitative analysis of promoter efficacy 
The comparative analysis of H-PPRV expression in OA3 TS cells infected with the three 
recombinant capripoxviruses using different promoters is shown on figure 1. The fluorescence 
obtained with KS1 represents the background. The highest level of H production was observed 
with the recombinant where the gene of this protein is under the control of the promoter p7.5, 
followed by that with promoter PS and pATI16p7.5.  
 
M1
 
Figure 1: In vitro comparison of expression level of PPRV H protein under different 
promoters in capripox genome. Vero cells were infected at the same MOI with different 
recombinant capripoxviruses in comparison with non recombinant capripoxvirus (KS1). 
The H gene was under p7.5, PS or pATI16p7.5 promoters. 
Screening test for animal selection 
All sera samples collected from 80 (eighty) goats were tested for the presence of 
antibodies to the haemagglutinin protein of PPRV and RPV. The results showed that seven out 
of eighty (8.7%) were positive for PPRV antibodies and four other (5%) were doubtful (see 
P7.5 = 66% 
PS = 43% 
pATI16p7.5 = 14% 
KS1 =  2%  
PS 
KS1 
P7.5       
pATI16p7.5 
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table 2). All positive and doubtful animals were immediately culled from the group. The 
remaining 69 (sixty nine) were negative for PPRV. All 80 (eighty) goats were negative for RPV 
(table 2). Those sixty nine (69) PPR seronegative goats were selected for the animal experiment. 
 
No. of 
Samples  
cELlSA 
Antibody test  
Number 
Positive  
Percentage 
Positive  
Doubtful Percentage 
Doubtful  
Total 
Negative 
80 PPRV  7 8.7 4 5 69 
80 RPV  0 0 0 0 80 
Table 2: Peste des Petits Ruminants Virus (PPRV) and Rinderpest Virus (RPV) antibodies 
in the sera collected from test animals, Debre-Zeit, Ethiopia.  
 
Evaluation of the Different Capripox/HPPR Recombinant viruses 
in the protection of Goats against PPR 
Vaccinated animals remained healthy after vaccination. Three weeks later, they were 
submitted to PPR virulent challenge along with their control contacts. Three to four days later, 
all controls became sick with the following signs summarized in table 3: hyperthermia (rectal 
temperature at above 39°C), nasal discharge, lacrymation, mouth ulcerations and coughing. 
Some showed diarrhoea. There were important changes on the lymph nodes, showing different 
level in increase of size (table 3). Three out of 10 of those control goats died before the end of 
the experiment. All animals which were vaccinated with either the classical attenuated PPR 
vaccine or the recombinant capripox/F PPR recombinant virus were perfectly protected against 
the virulent challenge. Animals which have been inoculated with the recombinant in which the 
promoter p7.5 is used resisted to the challenge except the one which had received the dose of 0.1 
TCID50. This later had rectal temperature greater than 39 °C for 3 days (see figure 2). Among 
the goats which were inoculated with recombinant virus which has the synthetic promoter, those 
with doses of 0.1 and 1 TCID50 virus had fever for a couple of days. The group of animals which 
had received the recombinant with the hybrid promoter was the most reactive group after the 
virulent challenge. Indeed, apart from animals which were inoculated with the recombinant at 
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the dose of 1000 TCID50, all other had fever for at least one day. One of the animals with the 
dose of 0.1 TCID50 was so sick that it was euthanized humanely. 
 
 
 
Day 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Mean T° 
record 37.9 38.6 39.1 39.7 40.2 40.4 40.2 40.0 39.8 39.7 39.2 39.0 39.3 39.1 
Nasal 
discharge    6/10 6/10 6/10 5/10 3/10       
Lacrimation     6/10 6/10 5/10       
 
Mouth 
ulcerations     5/10 5/10 5/10 4/10       
Coughing    3/10 5/10 5/10 4/10 3/10 3/10     
 
Diarrhoea        3/10 3/10 2/10 1/10   
 
Lymph 
nodes     
Swo
llen         
 
Mortality*          1 1 1 2  
 
Table 3: Average body temperature records, necropsy findings and mortality of 
unvaccinated control animals from all experimental groups (2 control goats in each 
group). * Number of animals found dead or sacrificed for human reason. 
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Figure 2: Temperature records of the five goat groups vaccinated with recombinant capripoxviruses. Three weeks after capripoxvirus 
vaccination, the goats were challenged with a virulent strain of PPRV. Curves represented the average result for the corresponding group. 
 
A. Comparison of groups one, two and three. 
 
 
                                     
 
 
 
 
 
 
 
 
 
 
 
                                                    a) Rec H-P7.5                                                                                                  b) Rec H-PS 
 
                                                                                                                                                          
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                         c) Rec.H- pATI16p7.5
Fig.2-1: Temperature record for group One (Rec.H-P7.5)
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Fig.2-2: Temperature record for group Two (Rec.H-ps)
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Fig. 2-3: Temperature record for group Three (Rec.H-pATI16p7.5)
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B. Comparison of groups four and five 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          
                      
 
                                   a) Rec F-PPR                                                                                                 b) Classic PPR 
 
 
 
Fig.2-4: Temperature record for group Four (Rec. F-PPR) 
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Fig. 2-5: Temperature record for group Five (Classic PPR)          
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Conclusion 
 
In an attempt to develop a very efficient recombinant capripox-based vaccine 
expressing H of PPRV, we have compared the relative strength of three poxvirus promoters to 
drive the production of this recombinant protein. It is well known that in the vaccinia vector 
system both the amount of the antigen and the timing of its synthesis impact on the quality of 
the induced immunity, cytotoxic T lymphocytes being primed mainly if the antigen is 
synthesized at early stages of the virus infection (Coupar et al., 1986). This may be true for all 
poxviruses. Therefore, in our experiment with capripox virus, we have compared three 
poxvirus promoters which are effective at both early and late stages of virus infection: 
- (a) the vaccinia p7.5 promoter which is widely used in the construction of poxvirus-
based recombinant vaccines. 
- (b) a compact synthetic promoter which was proved to be stronger, about 50 times, 
than p7.5 in driving expression of protein (Chakrabarti et al., 1997). Antigens 
produced under the control of this promoter induce in animals both humoral and 
cellular immune responses as it is the case for the p7.5 promoter (Sutter et al., 
1994). 
- (c) a hybrid promoter (pATI16p7.5) made with the strong cowpox late promoter ATI 
and the early promoter sequence of p7.5 tandemly repeated 16 times. This promoter 
was shown to support high level of recombinant protein production (Jin et al., 1994).  
 
The production of the PPRV H protein by the three recombinant capripox/ H PPR was 
assessed in cell culture with the FACsorter after staining the cells with fluorescent dye-labeled 
antibody. This study has shown that for the PPRV H production in the capripox virus system, 
p7.5 promoter was the most efficient. It was followed by the synthetic promoter. In this 
system, pATI16p7.5 was the weakest promoter. The three different recombinant capripox/H 
PPR viruses were tested in the Debre-Berhan goat breed in Ethiopia. Upon challenge with the 
virulent strain PPRV India 1994/1, the minimum effective dose was 1 TCID50 for the 
recombinant with the promoter p7.5, 10 TCID50 for the recombinant with the synthetic 
promoter and 1000 TCID50 for the recombinant with pATI16p7.5. These results correlate well 
with the in vitro quantitative analysis of the promoter efficacy. However, they do no confirm 
previous data that were found with the synthetic and the hybrid promoters in the vaccinia 
system where they were directing high level of gene expression (Jin et al., 1994; Chakrabarti 
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et al., 1997). The minimal effective dose of the recombinant capripox/H PPR with the 
synthetic promoter, 10 TCID50, which was found in the Ethiopian experiment, confirmed the 
result of the previous test carried out on goats in the UK and reported in manuscript 3. In the 
animal experiment to compare the different capripox/H PPR recombinants, was included also 
the capripox/F PPR recombinant as a positive vaccine control with the classical attenuated 
PPR vaccine. Goats which were immunised with those vaccines were protected. The 
recombinant capripox/F PPR virus was used at the dose of 0.1 TCID50/goat. These results 
reproduced the ones obtained in experimental trials carried out in Article 1 in which a dose of 
0.1 PFU/goat was found protective. In both experiments, the PPRV F gene was under the 
control of the promoter p7.5. The minimal effective dose of the similar construction with the 
PPRV H gene to fully protect goats against a virulent PPR challenge was 1 to 10 TCID50. This 
confirms that fusion protein of morbilliviruses expressed in a context of capripoxvirus is more 
potent than H in the induction of protective immune response in the hosts.  
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GENERAL DISCUSSION 
 
AND CONCLUSION 
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Peste des petits ruminants (PPR) is a highly viral contagious disease which is 
threatening the production of nearly a billion of sheep and goats in Africa, Asia, the Middle 
and Near East. It is one of the diseases targeted by the FAO in its EMPRESS programme 
which aims at controlling some important transboundary animal diseases. Its economic 
importance has been highlighted by an international study which has identified it as one of the 
priority animal diseases to be considered in poverty alleviation policy in areas where it is 
endemic (Perry et al., 2002). This study has considered small ruminants as the only hosts of 
PPRV. However, considering the fact that this virus can infect and cause disease in cattle, 
buffaloes and camels in some unknown circumstances PPR has therefore even higher priority, 
particularly in the current situation where vaccination against rinderpest in cattle has been 
stopped (Mornet et al.; 1956, Govindarajan et al., 1997; Roger et al., 2000; 2001). For most 
of the countries where it is endemic, the disease control measure easy to be implemented is 
the vaccination. There is an effective attenuated PPR vaccine which provides a life long 
immunity to inoculated animals (Diallo et al., 1987). Unfortunately, and as pointed out in a 
recent report, very few countries are implementing systematic vaccination campaigns to 
protect sheep and goats against PPR (Diallo, 2004). This may be explained by many 
constraints of which are: lack of information and the cost of the logistic for small ruminant 
vaccination. Indeed, the majority of small ruminants are owned by poor farmers. They have 
little contact with field veterinarians and also cannot afford vaccination costs if they are not 
born by governments. Although sheep and goats are important for the livelihoods of those 
owners, unfortunately on international trade scale they are not considered as valuable 
individually as for cattle. Moreover, nearly all small ruminant trade are carried out between 
countries within PPR endemic zones so this disease, although being in the list of important 
animal diseases to be notified to the OIE, does not constitute a strong constraint in 
international animal exchange as do rinderpest and FMD for example. All those perceptions 
on small ruminants and PPR make unlikely the implementation of an internationally-funded 
global eradication programme in line to the strategy which has almost been completed for 
rinderpest. In addition, considering that small ruminant populations are very scattered and that 
a high number of animals are concerned by the vaccination against PPR, there is a need of an 
important logistic for vaccination campaigns that becomes costly. A way to cut down this cost 
is to address the control of more than one important disease in a single operation. The 
objective of our work was to develop such a tool by constructing a recombinant capripox-
based PPR vaccine able to protect small ruminants against both PPR and capripox, another 
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transboundary animal disease which is also part of the group of animal diseases to be notified 
to the OIE as PPR.  
In a first step, we have inserted into the capripoxvirus genome the cDNA corresponding 
to the fusion protein of PPRV. The resultant recombinant virus that was obtained was tested 
very effective as a dual vaccine to protect goats against both PPR and capripox infections. We 
then produced three other capripox-based recombinant viruses expressing the PPRV 
haemagglutinin protein under the control of three different poxvirus early/late promoters. 
Assuming that those new recombinants will not differ from the capripox/F PPR in their 
capacity to protect small ruminants against capripox infection, the foreign gene insertion site 
being the same in the TK gene of the capripox virus for all, they were tested only for their 
capacity to protect against PPR. Among the three recombinant capripox/H PPR viruses, the 
one where the expression of H was under the control of the promoter p7.5 was the most potent 
since its minimum effective dose was estimated to be 1 TCID50/animal, ten times more than 
the capripox/F PPR in which the same promoter was used. Although no quantification of the 
F production was made and compared with that of H, the difference in the efficacy of the 
capripox/F PPR and capripox/H PPR recombinant viruses using the same promoter may be 
due to the more immunoprotective capacity of F than that of H in the context of capripoxvirus 
expression. With the objective to improve the quality of the recombinant capripox/H PPR, the 
efficiency of three promoters in driving the expression of H was compared. In addition to the 
classical vaccinia virus promoter p7.5, the two other were the synthetic early/late promoter 
(PS) and the hybrid promoter pATI16p7.5. Previous reports indicated that the last two 
promoters were by far most efficient in the expression of foreign proteins by the vaccinia 
virus (Chakrabarti et al., 1997; Jin et al., 1994). We expected that one these two promoters 
will direct high level expression of PPRV H by the capripoxvirus, expectation based on the 
assumption that a promoter of a poxvirus is functional with all other poxviruses (Tripathy and 
Wittek, 1990; Kumar and Boyle, 1990). Unfortunately, our result was the opposite of what 
was obtained with the vaccinia virus system: the p7.5 was the most efficient. Although we 
have not tested the expression of the PPRV H in the vaccinia virus system, we think that the 
non-expected result we have obtained is linked to the very low efficiency of PS and 
pATI16p7.5 in capripox virus. Indeed although it is claimed that transcription factors and 
promoter function are conserved between poxviruses, at least within a subfamily (Broyles, 
2003), subtle differences in the efficiency of gene expression processes may exist between 
viruses. A comparative study has demonstrated differences between fowlpox and vaccinia 
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viruses in the efficiency of promoters to drive expression of the same gene (Boyle, 1992). 
Following our results, research has been launched in CIRAD-EMVT to look for a 
capripoxvirus promoter that may be used for efficient foreign gene expression by capripox-
based recombinant viruses. 
Meantime, the recombinants we have developed will be better evaluated during the 
project which has just started. One of the objectives of this project is to determine the duration 
of immunity provided by both capripox/F PPR and capripox/ H PPR recombinant viruses. 
They will have a real interest if they prove to confer a long-term immunity, at least 
comparable to the one induced by the classical PPR vaccine, i.e. about 3 years. Since these 
recombinant vaccines are to be used in PPR and capripox endemic areas, some animals may 
have either PPR or capripox pre-existing antibodies. The effect of this pre-existing immunity 
on the efficacy of capripox-based PPR recombinant vaccine has to be studied. In the case of 
vaccinia-based recombinant, there are conflicting reports on the effect of pre-existing 
antibodies. Some reports indicated that the recombinant vaccine is still effective in the 
presence of antibodies directed against either the foreign gene or the vaccinia vector itself 
(Flexner et al., 1988; Ramírez et al., 2000). However, others indicated that strong immune 
response against viral vector proteins was associated with a lower effective immune response 
against vector-expressed foreign antigens (Rooney et al., 1988; Kundig et al., 1993).  
One of the possible features of the capripox-based PPR recombinant vaccine is the 
thermotolerance since the areas for its potential use are of hot climate. A study has to be 
carried on both liquid and freeze-dried product to determine the conditions of storage and use 
of the recombinant capripox-PPR vaccine in the field.  
A major disadvantage of the current classical attenuated PPR homologous vaccine is 
that the antibody response it induces cannot be distinguished from that following a natural 
infection. This makes the sero-epidemiosurveillance of the disease impossible in endemic 
areas where a vaccination programme has to be or is being implemented. A way to combine 
both activities, vaccination and serosurveillance, for the better management of the disease 
would be the use of DIVA vaccines, the acronym used for vaccines which enable 
differentiation between infected and vaccinated animals (van Oirschot JT., 1999). The 
capripox-based PPR recombinant vaccine which carries only F and H protein genes, in 
conjunction use with a PPR ELISA kit in which the antigen is the PPRV nucleoprotein 
(Libeau et al., 1995), constitutes a DIVA vaccine which will facilitate the control of PPR by 
allowing both vaccination and seroepidemiosurveillance activities at the same time.  
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